October 12^th at 15:15
Hybrid event
Medisiina D  lecture hall Lauren 1 / Zoom

Prof. Simon L. Goodman, Science and Technology Program Manager, the Antibody Society, Germany
Integrins as drug targets

Professor Goodman will be holding his lecture about the topic of integrins as drug targets on-site in the Medisiina D lecture hall Lauren 1. If you wish to come on-site please  register latest Sunday October 10th
https://link.webropol.com/s/VP-Simon-Goodman

You can also follow the talk online via Zoom, where no registration is required:
https://utu.zoom.us/j/61710469294

Welcome everyone!

Simon L. Goodman is Science and Technology Program Manager for the Antibody Society. He gained his D.Phil in membrane biochemistry from the University of Sussex. His start-up biotechnology company works on antibody validation.  He spent many years at Merck inventing and developing peptide and antibody therapeutics targeting cell adhesion through phase 3 clinical trials in oncology. Prior to Merck, he did post-doctoral work at Max-Planck Society on cellular receptors for laminin, with Klaus von der Mark at Martinsried, Munich and Erlangen, and phenotypic antibody screens with Walter Birchmeier at MPI Tübingen. His work includes the first high resolution X-ray structures of integrins, in collaboration with Dr. Amin Arnaout (Harvard Medical School).  His career in academia and industry has resulted in over 100 peer-reviewed publications, reviews and in many patents.

October 12^th at 15:15
Hybrid event
Medisiina D  lecture hall Lauren 1 / Zoom

Prof. Simon L. Goodman, Science and Technology Program Manager, the Antibody Society, Germany
Integrins as drug targets

Professor Goodman will be holding his lecture about the topic of integrins as drug targets on-site in the Medisiina D lecture hall Lauren 1. If you wish to come on-site please  register latest Sunday October 10th
https://link.webropol.com/s/VP-Simon-Goodman

You can also follow the talk online via Zoom, where no registration is required:
https://utu.zoom.us/j/61710469294

Welcome everyone!

Simon L. Goodman is Science and Technology Program Manager for the Antibody Society. He gained his D.Phil in membrane biochemistry from the University of Sussex. His start-up biotechnology company works on antibody validation.  He spent many years at Merck inventing and developing peptide and antibody therapeutics targeting cell adhesion through phase 3 clinical trials in oncology. Prior to Merck, he did post-doctoral work at Max-Planck Society on cellular receptors for laminin, with Klaus von der Mark at Martinsried, Munich and Erlangen, and phenotypic antibody screens with Walter Birchmeier at MPI Tübingen. His work includes the first high resolution X-ray structures of integrins, in collaboration with Dr. Amin Arnaout (Harvard Medical School).  His career in academia and industry has resulted in over 100 peer-reviewed publications, reviews and in many patents.

October 11th at 11:15
Hybrid event
Medisiina D lecture hall Lauren 1 / Zoom

Prof. Simon L. Goodman, Science and Technology Program Manager, the Antibody Society, Germany
Drug discovery and how things are done in pharma

Professor Goodman will be holding his introductory lecture on-site in the Medisiina D Lecture Hall Lauren 1. If you wish to come on-site please register latest Sunday October 10^th
https://link.webropol.com/s/VP-Simon-Goodman

You can also follow the talk online via Zoom, where no registration is required:
https://utu.zoom.us/j/66366373791

Welcome everyone!

Simon L. Goodman is Science and Technology Program Manager for the Antibody Society. He gained his D.Phil in membrane biochemistry from the University of Sussex. His start-up biotechnology company works on antibody validation.  He spent many years at Merck inventing and developing peptide and antibody therapeutics targeting cell adhesion through phase 3 clinical trials in oncology. Prior to Merck, he did post-doctoral work at Max-Planck Society on cellular receptors for laminin, with Klaus von der Mark at Martinsried, Munich and Erlangen, and phenotypic antibody screens with Walter Birchmeier at MPI Tübingen. His work includes the first high resolution X-ray structures of integrins, in collaboration with Dr. Amin Arnaout (Harvard Medical School).  His career in academia and industry has resulted in over 100 peer-reviewed publications, reviews and in many patents.

Special seminar, program will be announced later

Zoom details 
https://utu.zoom.us/j/67279196618
Meeting ID: 672 7919 6618
Passcode: 878028

May 19^th at 13:00
Virtual event

We will be hosting Prof. Vincenzo Cerullo, Group leader of ImmunoViroTherapy Lab, University of Helsinki, for the talk. The duration of the talk is 30 mins followed by 15 mins of discussion and interaction with the speaker.
Title of the talk: “Dressing up viruses to fool cancer”

Flyer pdf

You can register here: http://bit.ly/cerullo. This link is active until 18th May 23:59.

Brief Bio about the speaker: Prof. Vincenzo Cerullo, Vince is professor of Biological Drug Development, Faculty of Pharmacy, Head of Drug Research Program, HiLIFE fellow, Translational Immunology Programme, University of Helsinki. Vince got his PhD at Centre for genetic Engineering (CENIGE) at University of Naples, Federico II in 2004, then he moved to Houston Texas (USA) for a postdoc at Baylor College of Medicine. In 2009 he moved to University of Helsinki where he worked as senior researcher until 2012 when he was awarded the tenure-track professorship and started the ImmunoViroTherapy Lab.  In these years IVTLab has raised more than 7 million Euros for research, including the prestigious ERC Consolidator Grant, ERC-PoC, HiLIFE fellow and Jane and Aatos Erkko Foundation grant. The group has produced tens of scientific papers and patents and has co-founded a multimillion spin-off company together with the University of Helsinki (VALO therapeutics). Vince has been awarded the Outstading Young Investigator award in 2014 by the European Society of Gene and cell Therapy and the Excellence in Research award by the American Society of Gene and Cell Therapy in 2015; he has been recently ranked number one globally, third in Europe and number one in the nordic in his own experitiese (oncolytic virotherapy) by expertscape.

One of Vince’s passion is science dissemination, this is why has been involved from the beginning in organizing the Science track in Slush, he has pitched himself on the Slush stage in 2015, 2016 and on the Slush Y Science stage in 2017 (www.slush.org). Among other things, he has also presented a TEDx talk on the importance of creativity in science (https://youtu.be/1btbElPnREI)

More details about research can be found here: https://www2.helsinki.fi/en/researchgroups/immunovirotherapy-lab/research

May 19^th at 13:00
Virtual event

We will be hosting Prof. Vincenzo Cerullo, Group leader of ImmunoViroTherapy Lab, University of Helsinki, for the talk. The duration of the talk is 30 mins followed by 15 mins of discussion and interaction with the speaker.
Title of the talk: “Dressing up viruses to fool cancer”

Flyer pdf

You can register here: http://bit.ly/cerullo. This link is active until 18th May 23:59.

Brief Bio about the speaker: Prof. Vincenzo Cerullo, Vince is professor of Biological Drug Development, Faculty of Pharmacy, Head of Drug Research Program, HiLIFE fellow, Translational Immunology Programme, University of Helsinki. Vince got his PhD at Centre for genetic Engineering (CENIGE) at University of Naples, Federico II in 2004, then he moved to Houston Texas (USA) for a postdoc at Baylor College of Medicine. In 2009 he moved to University of Helsinki where he worked as senior researcher until 2012 when he was awarded the tenure-track professorship and started the ImmunoViroTherapy Lab.  In these years IVTLab has raised more than 7 million Euros for research, including the prestigious ERC Consolidator Grant, ERC-PoC, HiLIFE fellow and Jane and Aatos Erkko Foundation grant. The group has produced tens of scientific papers and patents and has co-founded a multimillion spin-off company together with the University of Helsinki (VALO therapeutics). Vince has been awarded the Outstading Young Investigator award in 2014 by the European Society of Gene and cell Therapy and the Excellence in Research award by the American Society of Gene and Cell Therapy in 2015; he has been recently ranked number one globally, third in Europe and number one in the nordic in his own experitiese (oncolytic virotherapy) by expertscape.

One of Vince’s passion is science dissemination, this is why has been involved from the beginning in organizing the Science track in Slush, he has pitched himself on the Slush stage in 2015, 2016 and on the Slush Y Science stage in 2017 (www.slush.org). Among other things, he has also presented a TEDx talk on the importance of creativity in science (https://youtu.be/1btbElPnREI)

More details about research can be found here: https://www2.helsinki.fi/en/researchgroups/immunovirotherapy-lab/research

Janne Koskinen, ArcDia International Oy
Company perspective on R&D in clinical microbiology and virology

Organized in Zoom
https://utu.zoom.us/j/7562392825

2 ECTS
KAB24007 (UTU)
TK00BS28-3003 (ÅAU)

course description
detailed program

Registration latest April 13th via Nettiopsu (UTU) or Peppi (ÅAU)

If you are from other organization but would ilke to register, please contact the responsible teachers.

The course deals with basic concepts of sustainability, bioeconomy and circular economy. It gives an overview of current and potential bioeconomy in Finland, starting from biomass resources and advanced conversion technologies to national and EU strategies. Lectures are given by top experts from different fields in industry and academia and the course includes a virtual excursion to the Smart Chemistry Park, which is South Western Finland’s technology innovation park largely devoted to bioeconomy and cleantech.

Academic lecturers
Eva-Mari Aro, University of Turku
Markku Kulmala, Univesity of Helsinki
Henrik Grénman, Åbo Akademi University
Yagut Allahverdiyeva, University of Turku
Chunlin Xu, Åbo Akademi University
Pauli Kallio, University of Turku
Tekla Tammelin, FinnCERES Flagship
Mikko Pohjola, University of UTU

Industry lecturers
Maija Pohjakallio, Sulapac Ltd.
Lari Vähäsalo, CH Bioforce
Antoine Mialon, MetGen
Aino-Maija Lakaniemi, Neste Oy
Blanka Toukoniitty, Neste Oy
Elina Peltomaa, Algonomy
Linda Fröberg-Niemi, Smart Chemistry Park

The students are expected to keep a learning diary throughout the course and at the end of the course each student is assigned one of the topics to plunge into and to write a final report. The in-depth essay should describe the Finnish as well as global current situation, reflect on the future and include literature search.

The course lasts three full days and requires full attendance but in case of colliding events students need to be in contact with the responsible teachers in advance. More detailed program is available in SmartBio web pages www.smartbio.fi as well as in Moodle. The course is intended for advanced Master students as well as for PhD students.

Responsible teachers 
Prof. Yagut Allahverdiyeva (allahve@utu.fi)
Prof. Henrik Grénman (henrik.grenman@abo.fi)

2 ECTS
KAB24007 (UTU)
TK00BS28-3003 (ÅAU)

course description
detailed program

Registration latest April 13th via Nettiopsu (UTU) or Peppi (ÅAU)

If you are from other organization but would ilke to register, please contact the responsible teachers.

The course deals with basic concepts of sustainability, bioeconomy and circular economy. It gives an overview of current and potential bioeconomy in Finland, starting from biomass resources and advanced conversion technologies to national and EU strategies. Lectures are given by top experts from different fields in industry and academia and the course includes a virtual excursion to the Smart Chemistry Park, which is South Western Finland’s technology innovation park largely devoted to bioeconomy and cleantech.

Academic lecturers
Eva-Mari Aro, University of Turku
Markku Kulmala, Univesity of Helsinki
Henrik Grénman, Åbo Akademi University
Yagut Allahverdiyeva, University of Turku
Chunlin Xu, Åbo Akademi University
Pauli Kallio, University of Turku
Tekla Tammelin, FinnCERES Flagship
Mikko Pohjola, University of UTU

Industry lecturers
Maija Pohjakallio, Sulapac Ltd.
Lari Vähäsalo, CH Bioforce
Antoine Mialon, MetGen
Aino-Maija Lakaniemi, Neste Oy
Blanka Toukoniitty, Neste Oy
Elina Peltomaa, Algonomy
Linda Fröberg-Niemi, Smart Chemistry Park

The students are expected to keep a learning diary throughout the course and at the end of the course each student is assigned one of the topics to plunge into and to write a final report. The in-depth essay should describe the Finnish as well as global current situation, reflect on the future and include literature search.

The course lasts three full days and requires full attendance but in case of colliding events students need to be in contact with the responsible teachers in advance. More detailed program is available in SmartBio web pages www.smartbio.fi as well as in Moodle. The course is intended for advanced Master students as well as for PhD students.

Responsible teachers 
Prof. Yagut Allahverdiyeva (allahve@utu.fi)
Prof. Henrik Grénman (henrik.grenman@abo.fi)

Alesia Levanova, University of Helsinki
Purification and analysis of small RNA molecules using asymmetrical flow field-flow fractionation (AF4)

Organized in Zoom
https://utu.zoom.us/j/7562392825

Karolina Louvanto, Methylation markers in cervical cancer screening
Akira Takeda, Stromal and immune cell interactions in health and disease

Zoom details
https://utu.zoom.us/j/67279196618
Meeting ID: 672 7919 6618
Passcode: 878028

Tom Wiklund, Åbo Akademi University
Bacteriophages as biocontrol agents for cold water disease in farmed rainbow trout

Organized in Zoom
https://utu.zoom.us/j/7562392825

Turku Cancer Research Society and FICAN West welcome you to join a seminar afternoon “State-of-the-art methodologies in cancer research”. It will be an online meeting via Zoom:

https://utu.zoom.us/j/61464679658
ID: 614 6467 9658
Passcode: 365521

Programme

Session I:
13.00-13.25 Riikka Lund “Supporting high-level research with state-of-the-art tools for genomics”
13.25-13.50 Hongbo Zhang “Advanced Materials and Nanotechnology on Cancer Treatment” (changed)
13.50-14.15 Mari Suominen “Learning curve for using CD34 engrafted humanized mice”
14.15-14.40 Tove Grönroos “New applications in animal PET/CT imaging”

Break

Session II:
15.00-15.25 Christoffer Löf “The CRISPR toolkit in cancer research” (changed)
15.25-15.50 Pekka Ruusuvuori “Artificial intelligence for cancer diagnostics and grading” (changed)
15.50-16.15 Sofia Khan “Where lies the power of genome-wide association studies (GWAS)”
16.15-16.30 Discussion and closing

Turku Doctoral Programme in Molecular Medicine (TuDMM) and the Finnish Euro-BioImaging Node is happy to announce a course “Basic Concepts of Bioimage Analysis” taking place in Turku BioCity between 12th-14th of June. The course will start at 12:00 on the 12th of June and complete at 17:00 on the 14th of June.

The course is aimed at graduate students, post-doctoral researchers, and everyone else who has background in imaging and microscopy and wish to gain additional insights into image analysis.

The 3-day course aims to cover the basics of image analysis and ethics involved in image analysis, fundamental concepts including convolution, segmentation, and many others with a hands-on practical component using ImageJ image analysis software working on participants’ own image analysis problems.

The maximum number of participants is 25 with participants selected based on their imaging background and suitability for the course.

More information here

Please register here: https://link.webropolsurveys.com/S/725C6B9DC91D0404

We are looking forward to your participation in this course.

Turku Doctoral Programme in Molecular Medicine (TuDMM) and the Finnish Euro-BioImaging Node is happy to announce a course “Basic Concepts of Bioimage Analysis” taking place in Turku BioCity between 12th-14th of June. The course will start at 12:00 on the 12th of June and complete at 17:00 on the 14th of June.

The course is aimed at graduate students, post-doctoral researchers, and everyone else who has background in imaging and microscopy and wish to gain additional insights into image analysis.

The 3-day course aims to cover the basics of image analysis and ethics involved in image analysis, fundamental concepts including convolution, segmentation, and many others with a hands-on practical component using ImageJ image analysis software working on participants’ own image analysis problems.

The maximum number of participants is 25 with participants selected based on their imaging background and suitability for the course.

More information here

Please register here: https://link.webropolsurveys.com/S/725C6B9DC91D0404

We are looking forward to your participation in this course.

Kati Kemppainen (Sahlgren lab): Introduction to the Cell Fate Lab

Maria Georgiadou (Orion Pharma): Making the transition – how to become a scientist in the industry

Kati Kemppainen (Sahlgren lab): Introduction to the Cell Fate Lab

Maria Georgiadou (Orion Pharma): Making the transition – how to become a scientist in the industry

Spring Seminar Event – Prostate Cancer:

13-13.05 Maria Sundvall – Opening and introduction

13.05-13.25 Peter Boström “Treatment of localized prostate cancer”

13.25-13.45 Heikki Minn “Molecular imaging in prostate cancer”

13.45-14.30 Steven Bova “Evolution of lethal prostate cancer at primary and metastatic sites: Can we identify what is important?”

14.30-15.00 Coffee break & Sponsors talk

15.00-15.20 Laura Elo ”How machine learning can improve treatment of prostate cancer”

15.20-15.40 Riikka Oksala “Androgen signaling axis as drug target in castration-resistant prostate cancer”

15.40-16.00 Kirsi Ketola “Cellular plasticity in lethal neuroendocrine prostate cancer”

16.00-16.30 Presentations by winners of grants

16.30 Sparkling wine and snacks

Register by email no later than 3.5.2019: contact-tcrs@lists.utu.fi

Printable programme here

Spring Seminar Event – Prostate Cancer:

13-13.05 Maria Sundvall – Opening and introduction

13.05-13.25 Peter Boström “Treatment of localized prostate cancer”

13.25-13.45 Heikki Minn “Molecular imaging in prostate cancer”

13.45-14.30 Steven Bova “Evolution of lethal prostate cancer at primary and metastatic sites: Can we identify what is important?”

14.30-15.00 Coffee break & Sponsors talk

15.00-15.20 Laura Elo ”How machine learning can improve treatment of prostate cancer”

15.20-15.40 Riikka Oksala “Androgen signaling axis as drug target in castration-resistant prostate cancer”

15.40-16.00 Kirsi Ketola “Cellular plasticity in lethal neuroendocrine prostate cancer”

16.00-16.30 Presentations by winners of grants

16.30 Sparkling wine and snacks

Register by email no later than 3.5.2019: contact-tcrs@lists.utu.fi

Printable programme here

Hussein Al-Akhrass SorLA – a novel oncogenic regulator of HER2-amplified breast cancer

Minna Piipponen Long non-coding RNAs in cutaneous squamous cell carcinoma

Hussein Al-Akhrass SorLA – a novel oncogenic regulator of HER2-amplified breast cancer

Minna Piipponen Long non-coding RNAs in cutaneous squamous cell carcinoma

Maija Hollmen Converting cold tumors hot -A macrophage targeted approach

Sami Ventelä New tools to diagnose and treat head and neck squamous cell carcinoma (HNSCC)

Maija Hollmen Converting cold tumors hot -A macrophage targeted approach

Sami Ventelä New tools to diagnose and treat head and neck squamous cell carcinoma (HNSCC)

Valeriy Paramonov Profiling Notch signalling in digestive endocrine cancers

Maria Gardberg Exploring novel fusion genes in glioblastoma

Valeriy Paramonov Profiling Notch signalling in digestive endocrine cancers

Maria Gardberg Exploring novel fusion genes in glioblastoma

DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM
TRANSLATING MOLECULES TO TREATMENTS II

9.00-9.10 Opening words by Professor Lea Sistonen

9.10-10.00 Thomas Kirkegaard Jensen Orphazyme – From Biology to Bedside

Thomas Kirkegaard Jensen is a PhD and Chief Scientific Officer of Orphazyme ApS in Denmark. Orphazyme develops new therapies for patients suffering from protein-misfolding diseases with no or limited treatment options available. Orphazyme was founded on the initial discovery made by Thomas during his doctoral studies in the laboratory of Professor Marja Jäättelä at the Danish Cancer Society, in which they found that the molecular chaperone, heat shock protein 70, reverts the pathology associated with lysosomal storage diseases. Based on this finding the company develops of new treatments for lysosomal storage diseases.

10.00-10.20 Coffee break

10.20-11.10 Rajwinder Lehal From Cell to Cellestia – Transition of a PhD Project Into a Drug Development Company

Rajwinder Lehal is a PhD and co-founder of Cellestia Biotech AG in Switzerland. The aim of Cellestia Biotech is to develop innovative therapeutics for cancer treatment. At Cellestia Biotech, he is Chief Scientific Officer and serves on the Board of Directors. Cellestia Biotech has developed a targeted therapy designed to treat cancers resulting from a mutation of the Notch gene. Molecule CB-103, discovered by Rajwinder Lehal during his doctoral studies in Professor Freddy Radtke’s laboratory at EPFL, cuts off Notch signals leading to cell death of cancer cells.

11.10-12.00 Mads Daugaard Leveraging Placental Malaria Tropism for Cancer Therapeutic and Diagnostic Applications

Mads Daugaard is an Assistant Professor and group leader at Vancouver Prostate Centre at University of British Columbia and the Co-founder and Chairman of the Board of Directors of three biotech companies; VAR2 Pharmaceuticals, OncoMal and VarCT Diagnostics in Canada. Mads is a molecular biologist specialized in tumour-associated stress signaling pathways and tumour targeting systems. His research focuses on alternative polyadenylation of mRNAs, chromatin context-dependent DNA repair, development of resistance to chemotherapy, and immune evasion mechanisms in cancer. Another aspect of Mads’ research relates to discovery and development of novel tumour targeting systems based on parasite-derived recombinant proteins relevant for therapeutic and diagnostic applications in cancer.

12.30-14.00 Round table lunch with speakers
Round table discussions including lunch for students and postdocs in groups of 10 students/postdocs per speaker. The 30 first to register will be admitted.

Register before Friday January 11th  at https://survey.abo.fi/lomakkeet/10837/lomake.html

For more information, contact Annika Meinander, e-mail: annika.meinander@abo.fi

DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM
TRANSLATING MOLECULES TO TREATMENTS II

9.00-9.10 Opening words by Professor Lea Sistonen

9.10-10.00 Thomas Kirkegaard Jensen Orphazyme – From Biology to Bedside

Thomas Kirkegaard Jensen is a PhD and Chief Scientific Officer of Orphazyme ApS in Denmark. Orphazyme develops new therapies for patients suffering from protein-misfolding diseases with no or limited treatment options available. Orphazyme was founded on the initial discovery made by Thomas during his doctoral studies in the laboratory of Professor Marja Jäättelä at the Danish Cancer Society, in which they found that the molecular chaperone, heat shock protein 70, reverts the pathology associated with lysosomal storage diseases. Based on this finding the company develops of new treatments for lysosomal storage diseases.

10.00-10.20 Coffee break

10.20-11.10 Rajwinder Lehal From Cell to Cellestia – Transition of a PhD Project Into a Drug Development Company

Rajwinder Lehal is a PhD and co-founder of Cellestia Biotech AG in Switzerland. The aim of Cellestia Biotech is to develop innovative therapeutics for cancer treatment. At Cellestia Biotech, he is Chief Scientific Officer and serves on the Board of Directors. Cellestia Biotech has developed a targeted therapy designed to treat cancers resulting from a mutation of the Notch gene. Molecule CB-103, discovered by Rajwinder Lehal during his doctoral studies in Professor Freddy Radtke’s laboratory at EPFL, cuts off Notch signals leading to cell death of cancer cells.

11.10-12.00 Mads Daugaard Leveraging Placental Malaria Tropism for Cancer Therapeutic and Diagnostic Applications

Mads Daugaard is an Assistant Professor and group leader at Vancouver Prostate Centre at University of British Columbia and the Co-founder and Chairman of the Board of Directors of three biotech companies; VAR2 Pharmaceuticals, OncoMal and VarCT Diagnostics in Canada. Mads is a molecular biologist specialized in tumour-associated stress signaling pathways and tumour targeting systems. His research focuses on alternative polyadenylation of mRNAs, chromatin context-dependent DNA repair, development of resistance to chemotherapy, and immune evasion mechanisms in cancer. Another aspect of Mads’ research relates to discovery and development of novel tumour targeting systems based on parasite-derived recombinant proteins relevant for therapeutic and diagnostic applications in cancer.

12.30-14.00 Round table lunch with speakers
Round table discussions including lunch for students and postdocs in groups of 10 students/postdocs per speaker. The 30 first to register will be admitted.

Register before Friday January 11th  at https://survey.abo.fi/lomakkeet/10837/lomake.html

For more information, contact Annika Meinander, e-mail: annika.meinander@abo.fi

Professor James M Musser, Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas

The many secret lives of group A streptococcus, a human flesh-eating pathogen

Professor James M Musser, Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas

The many secret lives of group A streptococcus, a human flesh-eating pathogen

DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM

TRANSLATING MOLECULES TO TREATMENTS I

13.00-13.10 Opening words by Associate Professor Diana Toivola

13.10-14.00 M. Bishr Omary Molecular Pathogenesis of Porphyria and Therapeutic Approaches Using Zebrafish Models

M. Bishr Omary is Professor of Molecular & Integrative Physiology, the H Marvin Pollard Professor of Gastroenterology, Professor of Internal Medicine, and Special Advisor on Research to the Dean at University of Michigan in Ann Arbor, USA. He is also guest professor in Drug Development and Diagnostics at Åbo Akademi University in Turku. Bishr is a world leader in the area of intermediate filamentsand their associated diseases, with special focus on the regulation and function of keratins and lamins in digestive organs. Another active area of research in his laboratory involves studying the mechanism of porphyrin mediated cell damage in the context of the genetic porphyria disorders. He currently utilizes high throughput drug screening approaches to identify compounds with potential therapeutic benefits for intermediate filament associated diseases and for porphyrias.

https://medicine.umich.edu/dept/molecular-integrative-physiology/bishr-omary-md-phd

14:00-14.50 Caroline Heckman Personalizing Patient Care to Overcome Drug Resistance in Hematological Malignancies

Caroline Heckman is a Group leader and Principal Investigator at the Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Sciences, University of Helsinki in Finland. Caroline’s research is focused on understanding the mechanisms driving disease progression and drug resistance in hematological malignancies. She also applies technologies for better translation of basic research results towards clinical implementation.

https://www.fimm.fi/en/research/groups/heckman

14.50-15.10 Coffee break

15.10-16.00 “The ABCs of a postdoc in the US” with M. Bishr Omary

This interactive session is open to all interested and will cover tips and advice on doing a postdoc in general and especially related to being a postdoc in US.

Register before Friday January 11th at https://survey.abo.fi/lomakkeet/10837/lomake.html

For more information, contact Diana Toivola, e-mail: diana.toivola@abo.fi

DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM

TRANSLATING MOLECULES TO TREATMENTS I

13.00-13.10 Opening words by Associate Professor Diana Toivola

13.10-14.00 M. Bishr Omary Molecular Pathogenesis of Porphyria and Therapeutic Approaches Using Zebrafish Models

M. Bishr Omary is Professor of Molecular & Integrative Physiology, the H Marvin Pollard Professor of Gastroenterology, Professor of Internal Medicine, and Special Advisor on Research to the Dean at University of Michigan in Ann Arbor, USA. He is also guest professor in Drug Development and Diagnostics at Åbo Akademi University in Turku. Bishr is a world leader in the area of intermediate filamentsand their associated diseases, with special focus on the regulation and function of keratins and lamins in digestive organs. Another active area of research in his laboratory involves studying the mechanism of porphyrin mediated cell damage in the context of the genetic porphyria disorders. He currently utilizes high throughput drug screening approaches to identify compounds with potential therapeutic benefits for intermediate filament associated diseases and for porphyrias.

https://medicine.umich.edu/dept/molecular-integrative-physiology/bishr-omary-md-phd

14:00-14.50 Caroline Heckman Personalizing Patient Care to Overcome Drug Resistance in Hematological Malignancies

Caroline Heckman is a Group leader and Principal Investigator at the Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Sciences, University of Helsinki in Finland. Caroline’s research is focused on understanding the mechanisms driving disease progression and drug resistance in hematological malignancies. She also applies technologies for better translation of basic research results towards clinical implementation.

https://www.fimm.fi/en/research/groups/heckman

14.50-15.10 Coffee break

15.10-16.00 “The ABCs of a postdoc in the US” with M. Bishr Omary

This interactive session is open to all interested and will cover tips and advice on doing a postdoc in general and especially related to being a postdoc in US.

Register before Friday January 11th at https://survey.abo.fi/lomakkeet/10837/lomake.html

For more information, contact Diana Toivola, e-mail: diana.toivola@abo.fi

Special guest seminar

Johan Hartman, Karolinska Institute, Sweden
Precision pathology – from molecule to drug development

Dr Hartman is a principal investigator at Karolinska Institutet, Dept of Oncology and Pathology. His research focuses on breast cancer diagnosis with emphasis on tumor heterogeneity and ex vivo drug profiling. He has co-published several papers on the role of heterogeneity and cancer stem cells for therapeutic resistance. His team also has interest in image analysis for histopathology. Proliferation is a central factor for breast tumorigenesis but also for subclassification of tumors. Hartmans team has worked many years to develop computer-assisted methods to classify breast cancers based on proliferation. Currently they are applying deep-learning algorithms to improve cancer diagnosis. Dr Hartman is a clinically active breast pathologist at Karolinska University Laboratory and head of the Swedish expert group in breast pathology (KVAST-bröstcancer).

Some selected papers:
Kim C, et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018 May 3

Ullah I, et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph-nodes. J Clin Invest. 2018 Apr 2

Ma R, et al. Estrogen receptor β as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst. 2017 Mar 1

Rantalainen M, et al. Sci Rep. 2016 Nov 30.

Stålhammar G, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016 Apr 29

Special guest seminar

Johan Hartman, Karolinska Institute, Sweden
Precision pathology – from molecule to drug development

Dr Hartman is a principal investigator at Karolinska Institutet, Dept of Oncology and Pathology. His research focuses on breast cancer diagnosis with emphasis on tumor heterogeneity and ex vivo drug profiling. He has co-published several papers on the role of heterogeneity and cancer stem cells for therapeutic resistance. His team also has interest in image analysis for histopathology. Proliferation is a central factor for breast tumorigenesis but also for subclassification of tumors. Hartmans team has worked many years to develop computer-assisted methods to classify breast cancers based on proliferation. Currently they are applying deep-learning algorithms to improve cancer diagnosis. Dr Hartman is a clinically active breast pathologist at Karolinska University Laboratory and head of the Swedish expert group in breast pathology (KVAST-bröstcancer).

Some selected papers:
Kim C, et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018 May 3

Ullah I, et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph-nodes. J Clin Invest. 2018 Apr 2

Ma R, et al. Estrogen receptor β as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst. 2017 Mar 1

Rantalainen M, et al. Sci Rep. 2016 Nov 30.

Stålhammar G, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016 Apr 29

Urpo Lamminmäki, University of Turku
Synthetic Antibodies – Affinity Tools for Unmet Needs

Host: Jukka Alinikula

Urpo Lamminmäki, University of Turku
Synthetic Antibodies – Affinity Tools for Unmet Needs

Host: Jukka Alinikula

Mikko Metsä-Ketelä, University of Turku
Development of C-nucleoside antibiotics for inhibition of bacterial RNA polymerases.

Host: Kirsi Gröndahl-Yli-Hannuksela.

Mikko Metsä-Ketelä, University of Turku
Development of C-nucleoside antibiotics for inhibition of bacterial RNA polymerases.

Host: Kirsi Gröndahl-Yli-Hannuksela.

Program:
14.45 Sparkling wine
15.15 Lauri Aaltonen, University of Helsinki – “Genome sequencing in intestinal cancer”
16.15 Johanna Hynninen, Turku University Hospital – “Ovarian Cancer – Clinical aspects and ongoing research projects”
16.50 PhD award –lecture
17.10 Snacks and drinks

Registrations by November 26 via email: contact-tcrs (at) lists.utu.fi
Please also indicate a possible special diet when registering.

Please renew your membership or become a member for 2018 by paying the 10 €  annual membership fee on the Society’s bank account before the seminar (FI7612093000051335,  Turun Syöpätutkijat Ry, please use your name as a refenrence).

Program:
14.45 Sparkling wine
15.15 Lauri Aaltonen, University of Helsinki – “Genome sequencing in intestinal cancer”
16.15 Johanna Hynninen, Turku University Hospital – “Ovarian Cancer – Clinical aspects and ongoing research projects”
16.50 PhD award –lecture
17.10 Snacks and drinks

Registrations by November 26 via email: contact-tcrs (at) lists.utu.fi
Please also indicate a possible special diet when registering.

Please renew your membership or become a member for 2018 by paying the 10 €  annual membership fee on the Society’s bank account before the seminar (FI7612093000051335,  Turun Syöpätutkijat Ry, please use your name as a refenrence).

Ilona Rissanen, University of Helsinki
Molecular architecture of hantaviruses: keys to infection and virus neutralization

Host: Sisko Tauriainen.

Ilona Rissanen, University of Helsinki
Molecular architecture of hantaviruses: keys to infection and virus neutralization

Host: Sisko Tauriainen.

Annukka Pietikäinen, University of Turku
Pathogenesis and diagnostics of Lyme borreliosis

Host: Jukka Hytönen.

Annukka Pietikäinen, University of Turku
Pathogenesis and diagnostics of Lyme borreliosis

Host: Jukka Hytönen.

Coffee/tea and snack available before the talks

The two speakers:

1. Guido Serini (University of Torino Medical School)

• Title of talk: “Mechanisms of β1 integrin activation and clustering in the control of endothelial cell adhesion and migration”. This will be unpublished data.
• If time allows, Prof Serini will also summarise some recent work on semaphorin, its co-receptor neuropilin 1 and new binding partners and the implications of these novel interactions in vascular morphogenesis and function.

In his earlier work, Prof Serini showed for the first time how endothelial class 3 semaphorins (SEMA3) signal through plexin receptors to inhibit integrins and allow vascular morphogenesis (Serini et al., Nature 2003). More recently, his research group rationally designed, generated and characterized a mutant, protease resistant, and easily purifiable superagonist SEMA3A protein isoform that represents a parenterally-deliverable drug that effectively normalizes the cancer vasculature (Gioelli et al., Sci. Transl. Med. 2018). His lab has also unveiled how vascular morphogenesis relies not only on integrin conformational activation, but also on dedicated signalling pathways that control the endocytosis and recycling of conformationally active integrins to adhesion sites in coordination with TGN-dependent polarized fibronectin secretion (Valdembri et al., PloS Biol. 2009; Sandri et al., Cell Res. 2012; Mana et al., Nat. Commun. 2016).

Prof. Serini will serve as Pranshu Sahgal’s PhD opponent on Friday 16^th November!

Selected publications (Guido Serini):

                Semaphorins and angiogenesis

• G. Serini*, V. Valdembri, S. Zanivan, G. Morterra, C. Burkhardt, F. Caccavari, L. Zammataro, L. Primo, L. Tamagnone, M. Logan, M. Tessier-Lavigne, M. Taniguchi, A.W. Püschel, and F. Bussolino*. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003, 424: 391-397. *Shared corresponding authorship.
• F. Maione, F. Molla, C. Meda, R. Latini, L. Zentilin, M. Giacca, G. Seano, G. Serini*, F. Bussolino*, and E. Giraudo*. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 2009, 119: 3356-3372. *Shared senior authorship.
• N. Gioelli, F. Maione, C. Camillo, M. Ghitti, D. Valdembri, N. Morello, M. Darche, L. Zentilin, G. Cagnoni, Y. Qiu, M. Giacca, M. Giustetto, M. Paques, I. Cascone, G. Musco, L. Tamagnone, E. Giraudo, and G. Serini. A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Sci. Transl. Med. 2018, 10: eaah4807.

                Active integrin traffic

• D. Valdembri, P.T. Caswell, K.I. Anderson, J.P. Schwarz, I. König, E. Astanina, F. Caccavari, J.C. Norman, M.J. Humphries, F. Bussolino, and G. Serini. Neuropilin−1/GIPC1 Signaling Regulates α5β1 Integrin Traffic and Function in Endothelial Cells. PLoS Biology 2009, 7:e1000025.
• C. Sandri, F. Caccavari, D. Valdembri, C. Camillo, S. Veltel, M. Santambrogio, L. Lanzetti, F. Bussolino, J. Ivaska, and G. Serini. The R-Ras/RIN2/Rab5 complex controls endothelial cell adhesion and morphogenesis via active integrin endocytosis and Rac signaling. Cell Res. 2012, 22:1479-1501.
• G. Mana, F. Clapero, E. Panieri, V. Panero, R. T. Böttcher, H.Y. Tseng, F. Saltarin, E. Astanina, K.I. Wolanska, M. R. Morgan, M.J. Humphries, M.M. Santoro, G. Serini*, and D. Valdembri*. PPFIA1 drives active α5β1 integrin recycling and controls fibronectin fibrillogenesis and vascular morphogenesis. Nat. Commun. 2016, 7: 13546. *Shared senior and corresponding authorship.

2. Stephanie Miserey-Linkei (Institut Curie, PSL Research University)

• Title of talk: “Getting out the Golgi complex thanks to the RAB6 GTPase”

Dr Miserey-Linkei is a talented senior researcher in the group of Prof. Bruno Goud in Institut Curie. She investigates the mechanisms regulating cellular transport with a focus on unravelling the role of Rab GTPases, the Golgi network and microtubules in this important biological process.

Selected publications (Stephanie Miserey-Linkei):

• Miserey-Lenkei S, Bousquet H, Pylypenko O, Bardin S, Dimitrov A, Bressanelli, G, Bonifay R, Fraisier V, Guillou C, Bougeret C, Houdusse A, Echard A, Goud B. Coupling fission and exit of RAB6 vesicles at Golgi hotspots through kinesin-myosin interactions. Nat Commun. 2017, 8(1):1254.
• Patwardhan A, Bardin S, Miserey-Lenkei S, Larue L, Goud B, Raposo G, Delevoye C. Routing of the RAB6 secretory pathway towards the lysosome related organelle of melanocytes. Nat Commun. 2017, 8:15835.
• Miserey-Lenkei S, Colombo MI. Small RAB GTPases Regulate Multiple Steps of Mitosis. Front Cell Dev Biol. 2016, 4:2. Review.
• Delevoye C, Miserey-Lenkei S, Montagnac G, Gilles-Marsens F, Paul-Gilloteaux P, Giordano F, Waharte F, Marks MS, Goud B, Raposo G. Recycling endosome tubule morphogenesis from sorting endosomes requires the kinesin motor KIF13A. Cell Rep. 2014, 6(3):445-54.
• Al Awabdh S, Miserey-Lenkei S, Bouceba T, Masson J, Kano F, Marinach-Patrice C, Hamon M, Emerit MB, Darmon M. A new vesicular scaffolding complex mediates the G-protein-coupled 5-HT1A receptor targeting to neuronal dendrites. J Neurosci. 2012, 32(41):14227-41.
• Miserey-Lenkei S, Waharte F, Boulet A, Cuif MH, Tenza D, El Marjou A, Raposo G, Salamero J, Héliot L, Goud B, Monier S. Rab6-interacting protein 1 links Rab6 and Rab11 function. Traffic. 2007, 8(10):1385-403.
• Miserey-Lenkei S, Couëdel-Courteille A, Del Nery E, Bardin S, Piel M, Racine V, Sibarita JB, Perez F, Bornens M, Goud B. A role for the Rab6A’ GTPase in the inactivation of the Mad2-spindle checkpoint. EMBO J. 2006, 25(2):278-89.

Coffee/tea and snack available before the talks

The two speakers:

1. Guido Serini (University of Torino Medical School)

• Title of talk: “Mechanisms of β1 integrin activation and clustering in the control of endothelial cell adhesion and migration”. This will be unpublished data.
• If time allows, Prof Serini will also summarise some recent work on semaphorin, its co-receptor neuropilin 1 and new binding partners and the implications of these novel interactions in vascular morphogenesis and function.

In his earlier work, Prof Serini showed for the first time how endothelial class 3 semaphorins (SEMA3) signal through plexin receptors to inhibit integrins and allow vascular morphogenesis (Serini et al., Nature 2003). More recently, his research group rationally designed, generated and characterized a mutant, protease resistant, and easily purifiable superagonist SEMA3A protein isoform that represents a parenterally-deliverable drug that effectively normalizes the cancer vasculature (Gioelli et al., Sci. Transl. Med. 2018). His lab has also unveiled how vascular morphogenesis relies not only on integrin conformational activation, but also on dedicated signalling pathways that control the endocytosis and recycling of conformationally active integrins to adhesion sites in coordination with TGN-dependent polarized fibronectin secretion (Valdembri et al., PloS Biol. 2009; Sandri et al., Cell Res. 2012; Mana et al., Nat. Commun. 2016).

Prof. Serini will serve as Pranshu Sahgal’s PhD opponent on Friday 16^th November!

Selected publications (Guido Serini):

                Semaphorins and angiogenesis

• G. Serini*, V. Valdembri, S. Zanivan, G. Morterra, C. Burkhardt, F. Caccavari, L. Zammataro, L. Primo, L. Tamagnone, M. Logan, M. Tessier-Lavigne, M. Taniguchi, A.W. Püschel, and F. Bussolino*. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003, 424: 391-397. *Shared corresponding authorship.
• F. Maione, F. Molla, C. Meda, R. Latini, L. Zentilin, M. Giacca, G. Seano, G. Serini*, F. Bussolino*, and E. Giraudo*. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 2009, 119: 3356-3372. *Shared senior authorship.
• N. Gioelli, F. Maione, C. Camillo, M. Ghitti, D. Valdembri, N. Morello, M. Darche, L. Zentilin, G. Cagnoni, Y. Qiu, M. Giacca, M. Giustetto, M. Paques, I. Cascone, G. Musco, L. Tamagnone, E. Giraudo, and G. Serini. A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Sci. Transl. Med. 2018, 10: eaah4807.

                Active integrin traffic

• D. Valdembri, P.T. Caswell, K.I. Anderson, J.P. Schwarz, I. König, E. Astanina, F. Caccavari, J.C. Norman, M.J. Humphries, F. Bussolino, and G. Serini. Neuropilin−1/GIPC1 Signaling Regulates α5β1 Integrin Traffic and Function in Endothelial Cells. PLoS Biology 2009, 7:e1000025.
• C. Sandri, F. Caccavari, D. Valdembri, C. Camillo, S. Veltel, M. Santambrogio, L. Lanzetti, F. Bussolino, J. Ivaska, and G. Serini. The R-Ras/RIN2/Rab5 complex controls endothelial cell adhesion and morphogenesis via active integrin endocytosis and Rac signaling. Cell Res. 2012, 22:1479-1501.
• G. Mana, F. Clapero, E. Panieri, V. Panero, R. T. Böttcher, H.Y. Tseng, F. Saltarin, E. Astanina, K.I. Wolanska, M. R. Morgan, M.J. Humphries, M.M. Santoro, G. Serini*, and D. Valdembri*. PPFIA1 drives active α5β1 integrin recycling and controls fibronectin fibrillogenesis and vascular morphogenesis. Nat. Commun. 2016, 7: 13546. *Shared senior and corresponding authorship.

2. Stephanie Miserey-Linkei (Institut Curie, PSL Research University)

• Title of talk: “Getting out the Golgi complex thanks to the RAB6 GTPase”

Dr Miserey-Linkei is a talented senior researcher in the group of Prof. Bruno Goud in Institut Curie. She investigates the mechanisms regulating cellular transport with a focus on unravelling the role of Rab GTPases, the Golgi network and microtubules in this important biological process.

Selected publications (Stephanie Miserey-Linkei):

• Miserey-Lenkei S, Bousquet H, Pylypenko O, Bardin S, Dimitrov A, Bressanelli, G, Bonifay R, Fraisier V, Guillou C, Bougeret C, Houdusse A, Echard A, Goud B. Coupling fission and exit of RAB6 vesicles at Golgi hotspots through kinesin-myosin interactions. Nat Commun. 2017, 8(1):1254.
• Patwardhan A, Bardin S, Miserey-Lenkei S, Larue L, Goud B, Raposo G, Delevoye C. Routing of the RAB6 secretory pathway towards the lysosome related organelle of melanocytes. Nat Commun. 2017, 8:15835.
• Miserey-Lenkei S, Colombo MI. Small RAB GTPases Regulate Multiple Steps of Mitosis. Front Cell Dev Biol. 2016, 4:2. Review.
• Delevoye C, Miserey-Lenkei S, Montagnac G, Gilles-Marsens F, Paul-Gilloteaux P, Giordano F, Waharte F, Marks MS, Goud B, Raposo G. Recycling endosome tubule morphogenesis from sorting endosomes requires the kinesin motor KIF13A. Cell Rep. 2014, 6(3):445-54.
• Al Awabdh S, Miserey-Lenkei S, Bouceba T, Masson J, Kano F, Marinach-Patrice C, Hamon M, Emerit MB, Darmon M. A new vesicular scaffolding complex mediates the G-protein-coupled 5-HT1A receptor targeting to neuronal dendrites. J Neurosci. 2012, 32(41):14227-41.
• Miserey-Lenkei S, Waharte F, Boulet A, Cuif MH, Tenza D, El Marjou A, Raposo G, Salamero J, Héliot L, Goud B, Monier S. Rab6-interacting protein 1 links Rab6 and Rab11 function. Traffic. 2007, 8(10):1385-403.
• Miserey-Lenkei S, Couëdel-Courteille A, Del Nery E, Bardin S, Piel M, Racine V, Sibarita JB, Perez F, Bornens M, Goud B. A role for the Rab6A’ GTPase in the inactivation of the Mad2-spindle checkpoint. EMBO J. 2006, 25(2):278-89.

Tomas Strandin, University of Helsinki
The role of endothelial cells in hantavirus pathogenesis.

Host: Pekka Kolehmainen

Tomas Strandin, University of Helsinki
The role of endothelial cells in hantavirus pathogenesis.

Host: Pekka Kolehmainen

Jari Nuutila, Päivi Jalava-Karvinen, University of Turku and University Hospital Turku
Flow cytometry in infection diagnostics.

Host: Sisko Tauriainen.

Jari Nuutila, Päivi Jalava-Karvinen, University of Turku and University Hospital Turku
Flow cytometry in infection diagnostics.

Host: Sisko Tauriainen.

Csilla Sipeky: Aggressive prostate cancer: from genetic basis to clinical translation

Pauliina Hartiala: Lymfactin trial – Combined adenoviral VEGF-C and lymph node transfer treatment for patients with breast cancer treatment associated lymphedema

Csilla Sipeky: Aggressive prostate cancer: from genetic basis to clinical translation

Pauliina Hartiala: Lymfactin trial – Combined adenoviral VEGF-C and lymph node transfer treatment for patients with breast cancer treatment associated lymphedema

Welcome words by the Dean, coffee, cake and sparkling wine. Music by Aura Brass Band in Medisiina D lobby

Opening programme (in Finnish) on Monday, 8 October at 2pm in Sakari Alhopuro lecture hall in Medisiina D

KUN LÄÄKETIEDE KOHTASI POLITIIKAN – YHTEISKUNNALLISIA PAINEITA LÄÄKETIETEELLISEN TIEDEKUNNAN VAIHEISSA
Vesa Vares, Professor of Political History, UTU

LÄÄKETIETEELLISEN TIEDEKUNNAN TÄHTIHETKIÄ JA TAITEKOHTIA
Timo Niitemaa, M.Soc.Sci, Communications Officer (emeritus), UTU

TULEVAISUUDEN NÄKYMIÄ
Markku Wilenius, Professor of Futures Studies UTU

Welcome to join the festive activities!

Programme of the festival week

Welcome words by the Dean, coffee, cake and sparkling wine. Music by Aura Brass Band in Medisiina D lobby

Opening programme (in Finnish) on Monday, 8 October at 2pm in Sakari Alhopuro lecture hall in Medisiina D

KUN LÄÄKETIEDE KOHTASI POLITIIKAN – YHTEISKUNNALLISIA PAINEITA LÄÄKETIETEELLISEN TIEDEKUNNAN VAIHEISSA
Vesa Vares, Professor of Political History, UTU

LÄÄKETIETEELLISEN TIEDEKUNNAN TÄHTIHETKIÄ JA TAITEKOHTIA
Timo Niitemaa, M.Soc.Sci, Communications Officer (emeritus), UTU

TULEVAISUUDEN NÄKYMIÄ
Markku Wilenius, Professor of Futures Studies UTU

Welcome to join the festive activities!

Programme of the festival week

Eleonora Mäkelä: Novel diagnostic markers in AML

Mari Suominen: Radium-223 dichloride as a dual inhibitor of the vicious cycle and tumor growth in breast and prostate cancer bone metastasis models

Eleonora Mäkelä: Novel diagnostic markers in AML

Mari Suominen: Radium-223 dichloride as a dual inhibitor of the vicious cycle and tumor growth in breast and prostate cancer bone metastasis models

Programme here

Programme here

Dr. Hans Hendriks, Hendriks Pharmaceutical Consulting

Coffee served at 14:45

Hans Hendriks, Ph.D., held positions in Cell Biology and Immunology at the Vrije Universiteit (Amsterdam, The Netherlands). After 17 years he joined the New Drug Development Office (now part of INC Research), Europe’s foremost oncology Contract Research Organisation (Amsterdam, The Netherlands), gaining 12 years experience leading international drug discovery and development collaborations. In addition, he served in various drug development and drug evaluation committees of the EORTC, Cancer Research UK and US National Cancer Institute, and held for 8 years a position in the Executive Board of the EORTC Biological Therapeutics Development Group.

He established Hendriks Pharmaceutical Consulting January 2000, an independent consultancy company providing services to small companies and biotechs in Oncology R&D. He is co-founder of the Biotherapy Development Association (Germany, 2001) and served on the Scientific Advisory Board of a German biotech company (2001-2003). He was the National Network Representative for The Netherlands in the Council of the European Association for Cancer Research (EACR), period 2013-2018, and received a  honorary EACR membership as of 2018.

From 2002-2006 Dr. Hendriks acted as Project Technical Assistant to the European Commission (DG Research) in the 5th Framework Programme (FP) overseeing 20 cancer-related EU-funded projects, served as expert evaluator in 5th, 6th, 7th FP and H2020 of the EU and acted as Administrative Manager for the FP6 CompuVac project (June 2008-October 2009). In addition, he assisted Austrian, Dutch, Italian, and Slovenian consortia in the preparation and submission of grant applications for the European Union’s 7th FP, H2020 and the Innovative Medicines Initiative 2.

He was successful in bringing the telomere targeting agent KML001 from early stage preclinical research to Phase I clinical studies (CCR 2008;14:4593-602) and is co-inventor of a US patent application (2009).

Hendriks Pharmaceutical Consulting is member of the Competence Network Life Science (www.conelis.org), an association of selected life science experts that provides top-tier consulting services to the pharmaceutical industry. It is a network of highly qualified and independent experts who can be contracted individually or as part of an interdisciplinary team.

Selected publications

Hendriks. H. et al., Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative, British Journal of Cancer, 2017.

Peters, GJ., Govaerts, A-S., Hendriks, H. for the EORTC-pharmacology and molecular mechanism group. The role of pharmacology in anticancer drug development, ADMET, 2018

Dr. Hans Hendriks, Hendriks Pharmaceutical Consulting

Coffee served at 14:45

Hans Hendriks, Ph.D., held positions in Cell Biology and Immunology at the Vrije Universiteit (Amsterdam, The Netherlands). After 17 years he joined the New Drug Development Office (now part of INC Research), Europe’s foremost oncology Contract Research Organisation (Amsterdam, The Netherlands), gaining 12 years experience leading international drug discovery and development collaborations. In addition, he served in various drug development and drug evaluation committees of the EORTC, Cancer Research UK and US National Cancer Institute, and held for 8 years a position in the Executive Board of the EORTC Biological Therapeutics Development Group.

He established Hendriks Pharmaceutical Consulting January 2000, an independent consultancy company providing services to small companies and biotechs in Oncology R&D. He is co-founder of the Biotherapy Development Association (Germany, 2001) and served on the Scientific Advisory Board of a German biotech company (2001-2003). He was the National Network Representative for The Netherlands in the Council of the European Association for Cancer Research (EACR), period 2013-2018, and received a  honorary EACR membership as of 2018.

From 2002-2006 Dr. Hendriks acted as Project Technical Assistant to the European Commission (DG Research) in the 5th Framework Programme (FP) overseeing 20 cancer-related EU-funded projects, served as expert evaluator in 5th, 6th, 7th FP and H2020 of the EU and acted as Administrative Manager for the FP6 CompuVac project (June 2008-October 2009). In addition, he assisted Austrian, Dutch, Italian, and Slovenian consortia in the preparation and submission of grant applications for the European Union’s 7th FP, H2020 and the Innovative Medicines Initiative 2.

He was successful in bringing the telomere targeting agent KML001 from early stage preclinical research to Phase I clinical studies (CCR 2008;14:4593-602) and is co-inventor of a US patent application (2009).

Hendriks Pharmaceutical Consulting is member of the Competence Network Life Science (www.conelis.org), an association of selected life science experts that provides top-tier consulting services to the pharmaceutical industry. It is a network of highly qualified and independent experts who can be contracted individually or as part of an interdisciplinary team.

Selected publications

Hendriks. H. et al., Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative, British Journal of Cancer, 2017.

Peters, GJ., Govaerts, A-S., Hendriks, H. for the EORTC-pharmacology and molecular mechanism group. The role of pharmacology in anticancer drug development, ADMET, 2018

Dr. Wah Ing Goh, the Agency for Science, Technology and Research (A*STAR) Microscopy Platform

Host: Camilo Guzman

Dear all,

We would like to invite you to a special seminar by   (https://www.a-star.edu.sg/imb/Tech-Platforms/IMB-Microscopy-Unit) in Singapore. Her seminar is entitled “The A*STAR Microscopy Platform and SingaScope – a microscopy core facility network for Singapore”. The seminar will take place in the TBC seminar room on the 5th Floor (Bio 5034a) and it is scheduled for Thursday 16th of August at 2:00 PM.

Dr. Goh is visiting the TBC as part of the “Job Shadowing International Program” of the Global BioImaging project and he will be shadowing our activities in bio imaging and promoting and active exchange between the Agency for Science, Technology and Research (A*STAR) and our Finnish ALM Node of Euro-BioImaging

For detailed information please see attached PDF file.

See you all there!

Dr. Wah Ing Goh, the Agency for Science, Technology and Research (A*STAR) Microscopy Platform

Host: Camilo Guzman

Dear all,

We would like to invite you to a special seminar by   (https://www.a-star.edu.sg/imb/Tech-Platforms/IMB-Microscopy-Unit) in Singapore. Her seminar is entitled “The A*STAR Microscopy Platform and SingaScope – a microscopy core facility network for Singapore”. The seminar will take place in the TBC seminar room on the 5th Floor (Bio 5034a) and it is scheduled for Thursday 16th of August at 2:00 PM.

Dr. Goh is visiting the TBC as part of the “Job Shadowing International Program” of the Global BioImaging project and he will be shadowing our activities in bio imaging and promoting and active exchange between the Agency for Science, Technology and Research (A*STAR) and our Finnish ALM Node of Euro-BioImaging

For detailed information please see attached PDF file.

See you all there!

Klaus Hedman, University of Helsinki

Host: Sisko Tauriainen

Klaus Hedman, University of Helsinki

Host: Sisko Tauriainen

FinLAS (Suomen koe-eläintieteen yhdistys ry) järjestää kevätseminaarin 18.5.2018 Turussa. Seminaari on tarkoitettu kaikille koe-eläinten parissa työskenteleville, koe-eläinalan ammattilaisille, tutkijoille ja opiskelijoille. Tapahtuma tarkempi ohjelma on tässä, ja kevätseminaarissa pääsemme kuulemaan koe-eläinkeskuksen johtajan Ulla-Marjut Jaakkolan läksiäisluennon.

Ilmoittautuminen: https://www.webropolsurveys.com/S/B9CD93BC3F165132.par

Lisätietoa: Emrah Yatkin (emryat@utu.fi)

FinLAS (Suomen koe-eläintieteen yhdistys ry) järjestää kevätseminaarin 18.5.2018 Turussa. Seminaari on tarkoitettu kaikille koe-eläinten parissa työskenteleville, koe-eläinalan ammattilaisille, tutkijoille ja opiskelijoille. Tapahtuma tarkempi ohjelma on tässä, ja kevätseminaarissa pääsemme kuulemaan koe-eläinkeskuksen johtajan Ulla-Marjut Jaakkolan läksiäisluennon.

Ilmoittautuminen: https://www.webropolsurveys.com/S/B9CD93BC3F165132.par

Lisätietoa: Emrah Yatkin (emryat@utu.fi)

Matti Waris, University of Turku

Host: Ilkka Julkunen

Matti Waris, University of Turku

Host: Ilkka Julkunen

Finnish Society for Bioinformatics is arranging a yearly Bioinformatics day, and the program includes lectures, poster session and workshops. The topics of the lectures are dealing with current bioinformatics research including both biosciences and computational modeling. This event gathers together people working with bioinformatics, both from universities and from companies around Finland.

Program of the event is available here.

Registration to the event from here.

Finnish Society for Bioinformatics is arranging a yearly Bioinformatics day, and the program includes lectures, poster session and workshops. The topics of the lectures are dealing with current bioinformatics research including both biosciences and computational modeling. This event gathers together people working with bioinformatics, both from universities and from companies around Finland.

Program of the event is available here.

Registration to the event from here.

Ilkka Julkunen, University of Turku

Host: Laura Kakkola

Ilkka Julkunen, University of Turku

Host: Laura Kakkola

Prof. John Lemasters
GlaxoSmithKline Distinguished Endowed Chair
Director, Center for Cell Death, Injury & Regeneration
Departments of Drug Discovery & Biomedical Sciences and Biochemistry & Molecular Biology
Medical University of South Carolina, USA

Host: Eeva-Liisa Eskelinen (eeva-liisa.eskelinen@utu.fi)
In case you wish to meet with Prof. Lemasters, please contact the host.

Dr. Lemasters’ research interests include the cellular and molecular mechanisms underlying toxic, hypoxic and ischemia-reperfusion injury to liver and heart. His laboratory applies new techniques of laser scanning confocal and multiphoton microscopy to characterize the physiology of single living cells, including the assessment of ion homeostasis, chelatable iron, mitochondrial function, electrical potentials, oxygen and nitrogen free radical formation, membrane permeability and other biochemical parameters during the pathogenesis of lethal cell injury.

 Selected publications

DeHart DN, Fang D, Heslop K, Li L, Lemasters JJ, Maldonado EN. Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol. 2018 Feb;148:155-162. doi: 10.1016/j.bcp.2017.12.022. Epub 2017 Dec 28.

Maldonado EN, DeHart DN, Patnaik J, Klatt SC, Gooz MB, Lemasters JJ. ATP/ADP turnover and import of glycolytic ATP into mitochondria in cancer cells is independent of the adenine nucleotide translocator. J Biol Chem. 2017 Oct 13;292(41):16969. doi: 10.1074/jbc.A116.734814.

Teplova VV, Kruglov AG, Kovalyov LI, Nikiforova AB, Fedotcheva NI, Lemasters JJ. Glutamate contributes to alcohol hepatotoxicity by enhancing oxidative stress in mitochondria. J Bioenerg Biomembr. 2017 Jun;49(3):253-264. doi: 10.1007/s10863-017-9713-0. Epub 2017 May 6.

Liu Q, H Rehman, Y Krishnasamy, RG Schnellmann, JJ Lemasters and Z Zhong. Improvement of liver injury and survival by JNK2 and iNOS deficiency in liver transplants from cardiac death mice. J Hepatol 2015, 63:68-74.

Prof. John Lemasters
GlaxoSmithKline Distinguished Endowed Chair
Director, Center for Cell Death, Injury & Regeneration
Departments of Drug Discovery & Biomedical Sciences and Biochemistry & Molecular Biology
Medical University of South Carolina, USA

Host: Eeva-Liisa Eskelinen (eeva-liisa.eskelinen@utu.fi)
In case you wish to meet with Prof. Lemasters, please contact the host.

Dr. Lemasters’ research interests include the cellular and molecular mechanisms underlying toxic, hypoxic and ischemia-reperfusion injury to liver and heart. His laboratory applies new techniques of laser scanning confocal and multiphoton microscopy to characterize the physiology of single living cells, including the assessment of ion homeostasis, chelatable iron, mitochondrial function, electrical potentials, oxygen and nitrogen free radical formation, membrane permeability and other biochemical parameters during the pathogenesis of lethal cell injury.

 Selected publications

DeHart DN, Fang D, Heslop K, Li L, Lemasters JJ, Maldonado EN. Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol. 2018 Feb;148:155-162. doi: 10.1016/j.bcp.2017.12.022. Epub 2017 Dec 28.

Maldonado EN, DeHart DN, Patnaik J, Klatt SC, Gooz MB, Lemasters JJ. ATP/ADP turnover and import of glycolytic ATP into mitochondria in cancer cells is independent of the adenine nucleotide translocator. J Biol Chem. 2017 Oct 13;292(41):16969. doi: 10.1074/jbc.A116.734814.

Teplova VV, Kruglov AG, Kovalyov LI, Nikiforova AB, Fedotcheva NI, Lemasters JJ. Glutamate contributes to alcohol hepatotoxicity by enhancing oxidative stress in mitochondria. J Bioenerg Biomembr. 2017 Jun;49(3):253-264. doi: 10.1007/s10863-017-9713-0. Epub 2017 May 6.

Liu Q, H Rehman, Y Krishnasamy, RG Schnellmann, JJ Lemasters and Z Zhong. Improvement of liver injury and survival by JNK2 and iNOS deficiency in liver transplants from cardiac death mice. J Hepatol 2015, 63:68-74.

Nicholas Kurniawan (PhD; assistant professor in biomedical engineering) and Aref Saberi (BSc) from the Eindhoven University of Technology (TU/e) will present their research as well as research and study opportunities available at their university next week at ÅAU Cell Biology.

Host: prof. Cecilia Sahlgren

13.15-14:00 Dr. Nicholas Kurniawan, Assistant professor in biomedical engineering, Eindhoven University of Technology (TU/e): Mechanobiology and tissue engineering

Dr. Kurniawan will present his research focused on the biophysical and mechanobiological aspects of cell-matrix interactions and related applications in regenerative medicine. In his research he combines expertise in biopolymer physics, cell biomechanics, and cytoskeletal rheology.

14:15-15:00 Aref Saberi, Eindhoven University of Technology (TU/e): Research activities and MSc programmes at Eindhoven University of Technology

An overview of research activities, educational programmes and student life at TU/e. The presentation is directed especially at students and researchers interested in doing an exchange abroad.

Kurniawan and Saberi will also give a lecture on stem cells and mechanosignaling on the ÅAU Stem cells course (223001.0) at 10-12 on the same day (in Kurssalen). Everyone interested is welcome to take part in the lecture as well.

Nicholas Kurniawan (PhD; assistant professor in biomedical engineering) and Aref Saberi (BSc) from the Eindhoven University of Technology (TU/e) will present their research as well as research and study opportunities available at their university next week at ÅAU Cell Biology.

Host: prof. Cecilia Sahlgren

13.15-14:00 Dr. Nicholas Kurniawan, Assistant professor in biomedical engineering, Eindhoven University of Technology (TU/e): Mechanobiology and tissue engineering

Dr. Kurniawan will present his research focused on the biophysical and mechanobiological aspects of cell-matrix interactions and related applications in regenerative medicine. In his research he combines expertise in biopolymer physics, cell biomechanics, and cytoskeletal rheology.

14:15-15:00 Aref Saberi, Eindhoven University of Technology (TU/e): Research activities and MSc programmes at Eindhoven University of Technology

An overview of research activities, educational programmes and student life at TU/e. The presentation is directed especially at students and researchers interested in doing an exchange abroad.

Kurniawan and Saberi will also give a lecture on stem cells and mechanosignaling on the ÅAU Stem cells course (223001.0) at 10-12 on the same day (in Kurssalen). Everyone interested is welcome to take part in the lecture as well.

Tapio Lönnberg, Turku Centre for Biotechnology

Host: Raine Toivonen

Tapio Lönnberg, Turku Centre for Biotechnology

Host: Raine Toivonen

Juha Vuononvirta, Imperial College of London

Host: Alex-Mikael Barkoff

Juha Vuononvirta, Imperial College of London

Host: Alex-Mikael Barkoff

Minna Poranen, University of Helsinki

Host: Veijo Hukkanen

Minna Poranen, University of Helsinki

Host: Veijo Hukkanen

Arno Hänninen, Univeristy of Turku

Host: Raine Toivonen

Arno Hänninen, Univeristy of Turku

Host: Raine Toivonen

Manu Tamminen, University of Turku

Host: Kirsi Gröndahl-Yli-Hannuksela

Manu Tamminen, University of Turku

Host: Kirsi Gröndahl-Yli-Hannuksela

Karolina Louvanto, University Hospital of Turku, University of Turku

Host: Stina Syrjänen

Karolina Louvanto, University Hospital of Turku, University of Turku

Host: Stina Syrjänen

Jaana Vuopio, University of Turku

Host: to be announced

Jaana Vuopio, University of Turku

Host: to be announced

Tiina Nokireki, Finnish Food Safety Authority

Host: Tytti Vuorinen

Tiina Nokireki, Finnish Food Safety Authority

Host: Tytti Vuorinen

BioCity research programme seminar, organized jointly by LIFESPAN and Receptor Programme and Turku Brain and Mind Center

Prof. Ulrik Gether, University of Copenhagen
The dopamine transporter: a key player in psychostimulant addiction and dopaminergic pathologies

Dr. Volker Eulenburg, University Hospital Leipzig, Clinics for Anaesthesiology and Intensive Care Medicine
Glycine transporter function in retina and dorsal horn – GlyT1 as a major regulator of glycine dependent neurotransmission

Host: Mika Scheinin (mschein@utu.fi)

Coffee/tea will be served at 15:00

BioCity research programme seminar, organized jointly by LIFESPAN and Receptor Programme and Turku Brain and Mind Center

Prof. Ulrik Gether, University of Copenhagen
The dopamine transporter: a key player in psychostimulant addiction and dopaminergic pathologies

Dr. Volker Eulenburg, University Hospital Leipzig, Clinics for Anaesthesiology and Intensive Care Medicine
Glycine transporter function in retina and dorsal horn – GlyT1 as a major regulator of glycine dependent neurotransmission

Host: Mika Scheinin (mschein@utu.fi)

Coffee/tea will be served at 15:00

Minna Niemelä, Turku Centre for Biotechnology

Host: Raine Toivonen

Minna Niemelä, Turku Centre for Biotechnology

Host: Raine Toivonen

This seminar is cancelled

Tapio Lönnberg, Turku Centre for Biotechnology

Host: Raine Toivonen

This seminar is cancelled

Tapio Lönnberg, Turku Centre for Biotechnology

Host: Raine Toivonen

Manu Tamminen, University of Turku

Host: Kirsi Gröndahl-Yli-Hannuksela

Manu Tamminen, University of Turku

Host: Kirsi Gröndahl-Yli-Hannuksela

Prof. John Marshall, Barts Cancer Institute, London, UK

Prof. John Marshall, Barts Cancer Institute, London, UK

Host: Johanna Ivaska

Prof. John Marshall has been studying the biology of tumour invasion for the last 25 years with a particular interest in the contributions made by the principal cell-matrix adhesion molecules called integrins. Prof Marshall’s group have identified integrin αvβ6, an epithelial-specific integrin not detectable on most normal tissues, as an important new therapeutic target in many cancers. In addition to understanding the function of the αvβ6 receptor in cancer, his group recently launched a clinical trial, in collaboration with Imanova to test the efficacy of an αvβ6-specific peptide for imaging solid cancers.

Selected publications

Raab-Westphal S, Marshall JF, Goodman SL. Integrins as Therapeutic Targets: Successes and Cancers. 2017 Cancers (Basel) 9(9).

Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RM, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, Itamochi H, Ghaem-Maghami S, Vallath S, Marshall JF, Maher J. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. (2017) Mol Ther. 25(1):259-273

Moore KM, Thomas GJ, Duffy SW et al. Therapeutic targeting of integrin αvβ6 in breast cancer. (2014) J Natl Cancer Inst vol. 106, (8)

Allen MD, Thomas GJ, Clark S et al. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. (2014) Clin Cancer Res (2) 344-357

Morgan MR, Jazayeri M, Ramsay AG, Thomas GJ, Boulanger MJ, Hart IR, Marshall JF. Psoriasin (S100A7) associates with integrin β6 subunit and is required for αvβ6-dependent carcinoma cell invasion. (2011) Oncogene 30(12):1422-35

Saha A, Ellison D, Thomas GJ, Vallath S, Mather SJ, Hart IR and Marshall JF. High resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin αvβ6. (2010) J Path. 222:52-63

You are warmly welcome to the Turku Cancer Research Society’s Christmas Seminar!

Topic of the seminar will be colorectal cancer and we have speakers presenting both basic research and clinical aspects.

Program
16.00 Welcome
PhD Thesis of the Year Award
-Break for snacks and drinks-
17.00 Annika Ålgars (Turku University Hospital)
“An oncologists perspective to CRC and a glimpse into own research data”
17.30 Diana Toivola (Åbo Akademi University)
“Colorectal cancer – Keratins in disease mechanism and disease modeling”
17.50 Elli Narvi (University of Turku)
“Response to EGFR inhibition plus oxaliplatin is determined by the sequence of administration in colorectal cancer”

You are warmly welcome to the Turku Cancer Research Society’s Christmas Seminar!

Topic of the seminar will be colorectal cancer and we have speakers presenting both basic research and clinical aspects.

Program
16.00 Welcome
PhD Thesis of the Year Award
-Break for snacks and drinks-
17.00 Annika Ålgars (Turku University Hospital)
“An oncologists perspective to CRC and a glimpse into own research data”
17.30 Diana Toivola (Åbo Akademi University)
“Colorectal cancer – Keratins in disease mechanism and disease modeling”
17.50 Elli Narvi (University of Turku)
“Response to EGFR inhibition plus oxaliplatin is determined by the sequence of administration in colorectal cancer”

MIKRO Seminars of Infection Biology and Infectious Diseases

Tuija Kantala, University of Turku

Host: Matti Waris

MIKRO Seminars of Infection Biology and Infectious Diseases

Tuija Kantala, University of Turku

Host: Matti Waris

Adjunct Prof. Timo Myöhänen, Drug Research Program, University of Helsinki

Host: Jukka Westermarck

Timo Myöhänen got his PhD (Pharmacology) in 2008 at University of Kuopio, and thereafter had post-doctoral visits in University of Antwerp (Belgium) and Georgetown University (Washington DC, USA) in 2010 and 2012. Dr. Myöhänen established his research group into Division of Pharmacology and Pharmacotherapy in University of Helsinki in 2011, got docentship in pharmacology in 2012 and is currently holding an Academy of Finland Research Fellow position. His research has focused on impact of a serine protease, prolyl oligopeptidase (PREP) and its pharmacological inhibition, on aggregation and toxicity of alpha-synuclein, a possible key player in cellular toxicity on Parkinson’s disease. Recent studies of Myöhänen lab have shown that PREP inhibitors can reduce the aggregation of alpha-synuclein and also enhance its clearance from cells by accelerating autophagy.

Lab website: http://blogs.helsinki.fi/prepinneuro/

Adjunct Prof. Timo Myöhänen, Drug Research Program, University of Helsinki

Host: Jukka Westermarck

Timo Myöhänen got his PhD (Pharmacology) in 2008 at University of Kuopio, and thereafter had post-doctoral visits in University of Antwerp (Belgium) and Georgetown University (Washington DC, USA) in 2010 and 2012. Dr. Myöhänen established his research group into Division of Pharmacology and Pharmacotherapy in University of Helsinki in 2011, got docentship in pharmacology in 2012 and is currently holding an Academy of Finland Research Fellow position. His research has focused on impact of a serine protease, prolyl oligopeptidase (PREP) and its pharmacological inhibition, on aggregation and toxicity of alpha-synuclein, a possible key player in cellular toxicity on Parkinson’s disease. Recent studies of Myöhänen lab have shown that PREP inhibitors can reduce the aggregation of alpha-synuclein and also enhance its clearance from cells by accelerating autophagy.

Lab website: http://blogs.helsinki.fi/prepinneuro/

Prof. Robert Viger, Laval University, Quebec, Canada

Prof. Robert Viger, Laval University, Quebec, Canada

Hosts: Nafis Rahman and Jorma Toppari

Anniina Rintala, University of Turku

Host: Jaana Vuopio

Anniina Rintala, University of Turku

Host: Jaana Vuopio

Florian Freudenberg, Translational Psychiatry Laboratory, Department of Psychiatry, Frankfurt University Hospital

Host: Michael Courtney

Florian Freudenberg, Translational Psychiatry Laboratory, Department of Psychiatry, Frankfurt University Hospital

Host: Michael Courtney

Prof. Duane A. Compton, Geisel School of Medicine at Dartmouth, Hanover, USA

Prof. Duane A. Compton, Geisel School of Medicine at Dartmouth, Hanover, USA

Host: Sofia Pruikkonen

Prof. Andrew Cant, Institute of Cellular Medicine, University of Newcastle, UK

Prof. Andrew Cant, Institute of Cellular Medicine, University of Newcastle, UK

Host: Ville Peltola

MIKRO Seminars of Infection Biology and Infectious Diseases

Johanna Ivaska, University of Turku

Host: Raine Toivonen

MIKRO Seminars of Infection Biology and Infectious Diseases

Johanna Ivaska, University of Turku

Host: Raine Toivonen

MIKRO Seminars of Infection Biology and Infectious Diseases

Ausra Domanska, University of Helsinki

Host: Petri Susi

MIKRO Seminars of Infection Biology and Infectious Diseases

Ausra Domanska, University of Helsinki

Host: Petri Susi

Prof. Mihai Netea, Faculty of Medical Sciences, Radboud University, Nijmegen, Netherlands

Prof. Mihai Netea, Faculty of Medical Sciences, Radboud University, Nijmegen, Netherlands:

Host: Riitta Lahesmaa ( rilahes@utu.fi )

SmartBIO Annual Meeting will be arranged on Monday November 6th 2017 in Kankaisten Linna (Kankaistentie 57, 21250 Masku). SmartBIO is one of the seven BioCity Turku Research Programmes for the years 2016-2020. In this one-day meeting the scientific program (all in English) includes two invited lecturers from industry partners and fifteen-minute talks from SmatBIO team members.

The registration is now open until Oct 29^th https://link.webropolsurveys.com/S/6116624FED0228CAYou can also find the registration from the SmartBIO web pages, together with the tentative program and more detailed information.
http://smartbio.fi/registration-smartbio-annual-meeting-2017-open

If you have any questions regarding the meeting please don’t hesitate to contact Maija Lespinasse (miholm@utu.fi).

SmartBIO Annual Meeting will be arranged on Monday November 6th 2017 in Kankaisten Linna (Kankaistentie 57, 21250 Masku). SmartBIO is one of the seven BioCity Turku Research Programmes for the years 2016-2020. In this one-day meeting the scientific program (all in English) includes two invited lecturers from industry partners and fifteen-minute talks from SmatBIO team members.

The registration is now open until Oct 29^th https://link.webropolsurveys.com/S/6116624FED0228CAYou can also find the registration from the SmartBIO web pages, together with the tentative program and more detailed information.
http://smartbio.fi/registration-smartbio-annual-meeting-2017-open

If you have any questions regarding the meeting please don’t hesitate to contact Maija Lespinasse (miholm@utu.fi).

Patrick Lewis, Reading School of Pharmacy, Reading, United Kingdom

Host: Eleanor Coffey

Patrick Lewis, Reading School of Pharmacy, Reading, United Kingdom

Host: Eleanor Coffey

Prof. Michael Hottiger, Department of Molecular Mechanisms of Disease, University of Zürich, Zürich, Switzerland

Prof. Michael Hottiger, Department of Molecular Mechanisms of Disease, University of Zürich, Zürich, Switzerland:

Host: Arto Pulliainen

The Hottiger-laboratory studies molecular regulatory mechanisms of inflammation, with special focus on the role of post-translation modifications in inflammatory signaling. They have contributed to the identification of protein ADP-ribosylation as a crucial process in the cellular response to detrimental stimuli, be it through genotoxicity, oxidative or metabolic stress, or excessive inflammation. Their current work focuses on the following questions: (i) Are ADP-ribosylation patterns cell-type specific or stimulus-specific, i.e. are there specific patterns that are associated with specific cell-physiological conditions? (ii) What are the modifiers (writer, binders, erasers) involved in those patterns? How can we specifically interfere with their activity to modulate the patterns? (iii) What are the regulatory mechanisms in ADP-ribosylation? How is the type and quantity of ADP-ribosylation patterns regulated? (iv) What are the downstream events of ADP-ribosylation, i.e. how does ADP-ribosylation alter the function of specific proteins and what is the effect on cell physiology? Most recently, the Hottiger-laboratory has studied the patterns of ADP-ribosylation using new systems biology approaches such as ADP-ribose specific high-resolution and quantitative mass spectrometry.

Website: http://www.dmmd.uzh.ch/en/research/hottiger.html

Selected publications:

Bisceglie L, Bartolomei G and Hottiger MO (2017) ADP-ribose-specific chromatin-affinity purification for investigating genome-wide or locus-specific chromatin ADP-ribosylation. Nature Protocols Sep;12(9):1951-1961.

Bilan V, Selevsek N, Kistemaker HAV, Abplanalp J, Feurer R, Filippov DV and Hottiger MO (2017) New quantitative mass spectrometry approaches reveal different ADP-ribosylation phases dependent on the levels of oxidative stress. Molecular & Cellular Proteomics May;16(5):949-958.

Bilan V, Leutert M, Nanni P, Panse C, Hottiger MO (2017) Combining Higher-Energy collision dissociation and electron-transfer/higher energy collision dissociation fragmentation in a product-dependent manner confidently assigns proteomewide ADP-ribose acceptor Sites. Analytical Chemistry Feb 7;89(3):1523-1530.

Martello R, Leutert M, Jungmichel S, Bilan V, Larsen SC, Young C, Hottiger MO and Nielsen ML (2016) Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue. Nature Communications Sep 30;7:12917. doi:

Leutert M, Pedrioli DML and Hottiger MO (2016) Identification of PARP-specific ADP-ribosylation targets reveals a regulatory function for ADP-ribosylation in transcription elongation. Molecular Cell Jul 21;63(2):181-183.

Hottiger MO (2015) SnapShot: ADP-ribosylation signaling. Molecular Cell Jun 18;58(6):1134-1134.e1.

Associate Professor Sven Nelander, Uppsala University, Uppsala, Sweden

 Receptor Program Seminar

Host: Jukka Westermarck (jukwes(at)utu.fi)

****
Sven Nelander is an Associate Professor at the Department of Immunology, Genetics and Pathology and Science for Life Laboratory at Uppsala University. His research group focuses on integrated approaches to cancer intervention, combining computational and experimental methods. A key diagnostic focus is GBM. Sven Nelander received his PhD in 2005 at the University of Gothenburg and trained as a postdoc at Memorial Sloan Kettering Cancer Center, NY (Sander lab). He joined Uppsala University in 2012.

Associate Professor Sven Nelander, Uppsala University, Uppsala, Sweden

 Receptor Program Seminar

Host: Jukka Westermarck (jukwes(at)utu.fi)

****
Sven Nelander is an Associate Professor at the Department of Immunology, Genetics and Pathology and Science for Life Laboratory at Uppsala University. His research group focuses on integrated approaches to cancer intervention, combining computational and experimental methods. A key diagnostic focus is GBM. Sven Nelander received his PhD in 2005 at the University of Gothenburg and trained as a postdoc at Memorial Sloan Kettering Cancer Center, NY (Sander lab). He joined Uppsala University in 2012.

Prof. Mads Gyrd-Hansen, Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK:

Host: Annika Meinander (annika.meinander(at)abo.fi) (Receptor)
**************

The Gyrd-Hansen laboratory studies molecular mechanisms governing pro-inflammatory signalling during innate immune responses. Through this, they aim to understand the molecular mechanisms that on one hand protect against pathogens, but that also contribute to chronic inflammation, tumor development and cancer progression. A central focus of the lab is to elucidate the role and regulation of non-degradative ubiquitin modifications in these processes. Ultimately, they aim to identify ubiquitin-handling factors that can be targeted to modulate inflammation and antagonize cancer. Professor Gyrd-Hansen’s recent work has focused on the role of Met1-linked ubiquitin chains (also known as linear ubiquitin chains) in inflammatory signaling. These chains are generated by the Linear UBiquitin Assembly Complex (LUBAC), which is a key component of inflammatory signaling pathways, including those activated downstream of the cytoplasmic PRRs NOD1 and NOD2 that serve as sensors for intracellular bacteria. They have uncovered and characterised several factors that regulate the function of LUBAC in signaling. Future work in the group will focus on elucidating the function, regulation and interplay of individual ubiquitin chain types (of which there are at least eight) in the cellular response to infection.

Website: http://www.ludwig.ox.ac.uk/mads-gyrd-hansen

Selected publications:

Gyrd-Hansen M. All roads lead to ubiquitin. Cell Death Differ. 2017 Jul;24(7):1135-1136. doi: 10.1038/cdd.2017.93.

Elliott PR, Leske D, Hrdinka M, Bagola K, Fiil BK, McLaughlin SH, Wagstaff J, Volkmar N, Christianson JC, Kessler BM, Freund SM, Komander D, Gyrd-Hansen M. SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. Mol Cell. 2016 Sep 15;63(6):990-1005. doi: 10.1016/j.molcel.2016.08.001.

Hrdinka M, Fiil BK, Zucca M, Leske D, Bagola K, Yabal M, Elliott PR, Damgaard RB, Komander D, Jost PJ, Gyrd-Hansen M. CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling. Cell Rep. 2016 Mar 29;14(12):2846-58. doi: 10.1016/j.celrep.2016.02.062.

Fiil BK, Gyrd-Hansen M. Met1-linked ubiquitination in immune signalling. FEBS J. 2014 Oct;281(19):4337-50. doi: 10.1111/febs.12944.

Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, Jost PJ, Ehl S, Mailand N, Gyrd-Hansen M. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med. 2013 Aug;5(8):1278-95. doi: 10.1002/emmm.201303090.

Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S, Mailand N, Choudhary C, Komander D, Gyrd-Hansen M. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell. 2013 Jun
27;50(6):818-830. doi: 10.1016/j.molcel.2013.06.004.

Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ, Gyrd-Hansen M. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell. 2012 Jun 29;46(6):746-58. doi: 10.1016/j.molcel.2012.04.014.

Prof. Mads Gyrd-Hansen, Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK:

Host: Annika Meinander (annika.meinander(at)abo.fi) (Receptor)
**************

The Gyrd-Hansen laboratory studies molecular mechanisms governing pro-inflammatory signalling during innate immune responses. Through this, they aim to understand the molecular mechanisms that on one hand protect against pathogens, but that also contribute to chronic inflammation, tumor development and cancer progression. A central focus of the lab is to elucidate the role and regulation of non-degradative ubiquitin modifications in these processes. Ultimately, they aim to identify ubiquitin-handling factors that can be targeted to modulate inflammation and antagonize cancer. Professor Gyrd-Hansen’s recent work has focused on the role of Met1-linked ubiquitin chains (also known as linear ubiquitin chains) in inflammatory signaling. These chains are generated by the Linear UBiquitin Assembly Complex (LUBAC), which is a key component of inflammatory signaling pathways, including those activated downstream of the cytoplasmic PRRs NOD1 and NOD2 that serve as sensors for intracellular bacteria. They have uncovered and characterised several factors that regulate the function of LUBAC in signaling. Future work in the group will focus on elucidating the function, regulation and interplay of individual ubiquitin chain types (of which there are at least eight) in the cellular response to infection.

Website: http://www.ludwig.ox.ac.uk/mads-gyrd-hansen

Selected publications:

Gyrd-Hansen M. All roads lead to ubiquitin. Cell Death Differ. 2017 Jul;24(7):1135-1136. doi: 10.1038/cdd.2017.93.

Elliott PR, Leske D, Hrdinka M, Bagola K, Fiil BK, McLaughlin SH, Wagstaff J, Volkmar N, Christianson JC, Kessler BM, Freund SM, Komander D, Gyrd-Hansen M. SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. Mol Cell. 2016 Sep 15;63(6):990-1005. doi: 10.1016/j.molcel.2016.08.001.

Hrdinka M, Fiil BK, Zucca M, Leske D, Bagola K, Yabal M, Elliott PR, Damgaard RB, Komander D, Jost PJ, Gyrd-Hansen M. CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling. Cell Rep. 2016 Mar 29;14(12):2846-58. doi: 10.1016/j.celrep.2016.02.062.

Fiil BK, Gyrd-Hansen M. Met1-linked ubiquitination in immune signalling. FEBS J. 2014 Oct;281(19):4337-50. doi: 10.1111/febs.12944.

Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, Jost PJ, Ehl S, Mailand N, Gyrd-Hansen M. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med. 2013 Aug;5(8):1278-95. doi: 10.1002/emmm.201303090.

Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S, Mailand N, Choudhary C, Komander D, Gyrd-Hansen M. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell. 2013 Jun
27;50(6):818-830. doi: 10.1016/j.molcel.2013.06.004.

Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ, Gyrd-Hansen M. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell. 2012 Jun 29;46(6):746-58. doi: 10.1016/j.molcel.2012.04.014.

For symposium program, click here.

Register latest Oct 22nd at: https://link.webropolsurveys.com/S/C1C0722937CB171E

For symposium program, click here.

Register latest Oct 22nd at: https://link.webropolsurveys.com/S/C1C0722937CB171E

Prof. Ville Kaila, Department of Chemistry, Technical University of Munich, Germany

Prof. Ville Kaila, Department of Chemistry, Technical University of Munich, Germany

Host: Paula Mulo

Description of research:

The research of Prof. Ville Kaila is focused on enzymatic and biomimetic catalysts for energy conversion. These processes are studied in respiratory and photosynthetic enzymes, but also in non-biological systems such as water-splitting molecular catalysts and molecular capsules. Prof. Kaila applies and develops powerful computational methodology ranging from ab initio quantum chemical techniques, hybrid quantum mechanics/classical mechanics (QM/MM) and subsystems methods, to large-scale classical molecular dynamics simulations, free-energy and continuum approaches.

Prof. Kaila will describe his recent work on the respiratory Complex I, and he will discuss how combination of experiments and multi-scale molecular simulations can provide a powerful methodology to obtain a molecular-level understanding of the structure, energetics, and dynamics of energy-capturing proteins, and how such methods can further be employed to engineer and design new proteins with desired target functions.

Selected publications:

Sharma V, Belevich G, Gamiz-Hernandez AP, Róg T, Vattulainen I, Wikström M, Hummer G, Kaila VRI (2015) Redox-Induced Activation of the Proton Pump in the Respiratory Complex I Proc. Natl. Acad. Sci. USA 112:11571-11576.

Kmita K, Wirth C, Warnau J, Guerrero-Castillo S, Hunte C, Hummer G, Kaila VRI, Zwicker K, Brandt U, Zickermann V. (2015) Accessory NUMM (NDUFS6) subunit harbors a Zn-binding site and is essential for biogenesis of mitochondrial complex I.  Proc. Natl. Acad. Sci. USA 112:5685-5690.

Boczek EE, Reefschläger LG, Dehling M, Struller T, Häusler E, Seidl A, Kaila VRI, Buchner J (2014) Conformational processing of oncogenic v-Src kinase by Hsp90. Proc. Natl. Acad. Sci. USA 112: E3189-3198.

Wikström M, Sharma V, Kaila VRI, Hosler J, Hummer G (2015) New perspectives on proton pumping in cellular respiration. Chem. Rev. 115, 2196-2221.

Kaila VRI , Schotte F, Hyun S-C, Hummer G, Anfinrud PA (2014) Reconciling contradictions in time-resolved x-ray structures of early intermediates in the photocycle of photoactive yellow protein Nature Chem 6:258-259.

Kaila VRI ,  Wikström M, Hummer G (2014) Electrostatics, Hydration, and Proton Transfer Dynamics in the Membrane Domain of Respiratory Complex I. Proc Natl Acad Sci USA 111, 6988-6993.

Schotte F, Hyun S-C,  Kaila VRI, Kamikubo H, Dashdorja N, Henry E, Graber T, Henning R, Wulff M, Hummer G, Kataoka M, Anfinruda PA (2012) Picosecond Photobiology: Watching a Signaling Protein Function in Real Time via Time-resolved Laue Crystallography. Proc Natl Acad Sci USA 109, 19256-19261.

Robert Lyle, Oslo University Hospital and University of Oslo, Norway

Host: Riikka Lund

Robert Lyle, Oslo University Hospital and University of Oslo, Norway

Host: Riikka Lund

Päivi Saavalainen, University of Helsinki
Host: Jorma Ilonen

Päivi Saavalainen, University of Helsinki
Host: Jorma Ilonen

Program

10.00     Coffee
10.15     Professor Noel Morgan, University of Exeter Medical School, UK: “Type 1 diabetes; evidence for disease heterogeneity”
11.00     Dr Sarah Richardson, University of Exeter Medical School, UK: “Is Type 1 Diabetes ‘Going Viral’?”
11.45     Dr. Mark Russell, Islet Biology Exeter, UK: “JAK/STAT Signalling in the Pathogenesis of Type 1 Diabetes”

Organised by:

The Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology
Turku Centre for LIFESPAN Research

Program

10.00     Coffee
10.15     Professor Noel Morgan, University of Exeter Medical School, UK: “Type 1 diabetes; evidence for disease heterogeneity”
11.00     Dr Sarah Richardson, University of Exeter Medical School, UK: “Is Type 1 Diabetes ‘Going Viral’?”
11.45     Dr. Mark Russell, Islet Biology Exeter, UK: “JAK/STAT Signalling in the Pathogenesis of Type 1 Diabetes”

Organised by:

The Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology
Turku Centre for LIFESPAN Research

Prof. Antti Poso, University of Eastern Finland, School of Pharmacy; Distinguished Guest Professor at the University of Tübingen in Germany

Host: Outi Salo-Ahen (outi.salo-ahen(at)abo.fi)

Prof. Antti Poso’s main research interest has been computer-aided drug design and early hit/lead identification and optimization. He did his post-doctoral research as a Humboldt-fellow in Düsseldorf with Prof. H.-D. Höltje (1997-1998) and after returning to Finland he started his own molecular modeling group. One of his first major research topics was to identify and optimize sirtuin inhibitors, especially against Sirt2. His group has also contributed substantially to the design of new compounds targeting different proteins of the endogenous cannabinoid system, such as CB1 and CB2 receptors as well as MAGL and FAAH enzymes. In recent years, his interest has shifted mainly to anti-cancer and anti-infective drug design, although he is also active in projects aiming to find new therapies to age-related macular degeneration. Besides his position at the University of Eastern Finland, he has also worked at FIMM (Helsinki) with Prof. Kallioniemi and since 2012 as a Guest Professor at the University of Tübingen (Germany) with professors Zender and Laufer.

About the seminar topic:

The seminar talk will discuss three separate projects in anti-cancer drug discovery. The introduction will give a brief overview of the methods used in Kuopio and Tübingen. The first case study is about a ribosomal drug targeting project and how early computational work is mandatory for a successful druggable target identification. The other two projects (targeting a kinase and DNA replication proteins) are both currently in the late lead-optimization phase.

Prof. Antti Poso, University of Eastern Finland, School of Pharmacy; Distinguished Guest Professor at the University of Tübingen in Germany

Host: Outi Salo-Ahen (outi.salo-ahen(at)abo.fi)

Prof. Antti Poso’s main research interest has been computer-aided drug design and early hit/lead identification and optimization. He did his post-doctoral research as a Humboldt-fellow in Düsseldorf with Prof. H.-D. Höltje (1997-1998) and after returning to Finland he started his own molecular modeling group. One of his first major research topics was to identify and optimize sirtuin inhibitors, especially against Sirt2. His group has also contributed substantially to the design of new compounds targeting different proteins of the endogenous cannabinoid system, such as CB1 and CB2 receptors as well as MAGL and FAAH enzymes. In recent years, his interest has shifted mainly to anti-cancer and anti-infective drug design, although he is also active in projects aiming to find new therapies to age-related macular degeneration. Besides his position at the University of Eastern Finland, he has also worked at FIMM (Helsinki) with Prof. Kallioniemi and since 2012 as a Guest Professor at the University of Tübingen (Germany) with professors Zender and Laufer.

About the seminar topic:

The seminar talk will discuss three separate projects in anti-cancer drug discovery. The introduction will give a brief overview of the methods used in Kuopio and Tübingen. The first case study is about a ribosomal drug targeting project and how early computational work is mandatory for a successful druggable target identification. The other two projects (targeting a kinase and DNA replication proteins) are both currently in the late lead-optimization phase.

Prof. W. Brent Derry, The Hospital for Sick Children and Department of Molecular Genetics, University of Toronto

Host: Annika Meinander (ÅAU Cell Biology and Receptor Programme)

The broad goal of Derry’s research is to understand how genes that are mutated in various diseases function in vivo. He uses the powerful genetics and functional genomics tools of the model organism Caenorhabditis elegans to understand how tumour suppressors and oncogenes control cell survival, genome stability and organism development. He is particularly interested in how cells communicate with one another to sculpt organs and make life or death decisions when challenged with stresses, such as chemotherapy and radiation. Derry also has a robust research program that is focused on understanding the mechanistic basis of the human neurovascular disease cerebral cavernous malformations (CCM). He is collaborating with an international team of scientists and clinicians to discover drugs that can be used to prevent the onset of CCM in humans.

Selected publications:
Pal, S., Lant, B., Yu, B., Tian, R., Tong, J., Krieger, J.R., Moran, M.F., Gingras, A.C., & Derry, W. B. CCM-3 Promotes C. elegans germline development by regulating vesicle trafficking cytokinesis and polarity. (2017) Current Biology. 27(6): 868-876.

Eroglu, M. & Derry, W.B. (2016) Your neighbours matter – non-autonomous control of apoptosis in development and disease. Cell Death and Differentiation. 23(7): 1110-1118.

Mateo, A.R, Kessler, Z., Jolliffe, A.K., McGovern, O., Yu, B., Nicolucci, A., Yanowitz, J.L. & Derry, W.B. (2016) The p53-like protein CEP-1 is required for meiotic fidelity in C. elegans. Current Biology. 26(9): 1148-1158.

Lant B, Yu B, Goudreault M, Holmyard D, Knight JD, Xu P, Zhao L, Chin K, Wallace E, Zhen M, Gingras AC, Derry WB. (2015) CCM-3/STRIPAK promotes seamless tube extension through endocytic recycling. Nature Communications. 6: 6449.

Baruah, A., Chang, H., Hall, M., Yuan, J., Gordon, S., Johnson, E., Shtessel, L.L., Yee, C., Hekimi, S., Derry, W.B., & Lee, S.S. (2014). CEP1, the Caenorhabditis elegans p53 homolog, mediates opposing longevity outcomes in mitochondrial electron transport chain mutants. PLoS Genetics. 10(2): e1004097.

Perrin, A.J., Gunda, M., Yu, B., Yen, K., Ito, S., Forster, S., Young, J., Tissenbaum, H.A. & Derry, W.B. (2013). Noncanonical control of C. elegans germline apoptosis by the insulin/IGF-1 and Ras/MAPK signaling pathways. Cell Death and Differentiation. 20(1): 97-107.

Ross, A.J., Li, M., Yu, B., Gao, M.X. & Derry, W.B. (2011). The EEL-1 ubiquitin ligase promotes DNA damage-induced germ cell apoptosis in C. elegans. Cell Death and Differentiation. 18(7): 1140-1149.

Ito, S., Greiss, S., Gartner, A. & Derry, W.B. (2010). Cell-nonautonomous regulation of C. elegans germ cell death by kri-1. Current Biology. 20(4): 333-338.

Gao, X. Liao, E., Yu, B., Wang, Y., Zhen, M. & Derry, W.B. (2008). The SCFFSN-1 ubiquitin ligase controls CEP-1/p53-dependent apoptosis in Caenorhabditis elegans. Cell Death and Differentiation. 15(6): 1054-1062.

Quevedo, C., Kaplan, D.R. & Derry, W.B. (2007). AKT-1 regulates DNA-damage induced germline apoptosis in C. elegans. Current Biology. 17(3): 286-292.

Prof. W. Brent Derry, The Hospital for Sick Children and Department of Molecular Genetics, University of Toronto

Host: Annika Meinander (ÅAU Cell Biology and Receptor Programme)

The broad goal of Derry’s research is to understand how genes that are mutated in various diseases function in vivo. He uses the powerful genetics and functional genomics tools of the model organism Caenorhabditis elegans to understand how tumour suppressors and oncogenes control cell survival, genome stability and organism development. He is particularly interested in how cells communicate with one another to sculpt organs and make life or death decisions when challenged with stresses, such as chemotherapy and radiation. Derry also has a robust research program that is focused on understanding the mechanistic basis of the human neurovascular disease cerebral cavernous malformations (CCM). He is collaborating with an international team of scientists and clinicians to discover drugs that can be used to prevent the onset of CCM in humans.

Selected publications:
Pal, S., Lant, B., Yu, B., Tian, R., Tong, J., Krieger, J.R., Moran, M.F., Gingras, A.C., & Derry, W. B. CCM-3 Promotes C. elegans germline development by regulating vesicle trafficking cytokinesis and polarity. (2017) Current Biology. 27(6): 868-876.

Eroglu, M. & Derry, W.B. (2016) Your neighbours matter – non-autonomous control of apoptosis in development and disease. Cell Death and Differentiation. 23(7): 1110-1118.

Mateo, A.R, Kessler, Z., Jolliffe, A.K., McGovern, O., Yu, B., Nicolucci, A., Yanowitz, J.L. & Derry, W.B. (2016) The p53-like protein CEP-1 is required for meiotic fidelity in C. elegans. Current Biology. 26(9): 1148-1158.

Lant B, Yu B, Goudreault M, Holmyard D, Knight JD, Xu P, Zhao L, Chin K, Wallace E, Zhen M, Gingras AC, Derry WB. (2015) CCM-3/STRIPAK promotes seamless tube extension through endocytic recycling. Nature Communications. 6: 6449.

Baruah, A., Chang, H., Hall, M., Yuan, J., Gordon, S., Johnson, E., Shtessel, L.L., Yee, C., Hekimi, S., Derry, W.B., & Lee, S.S. (2014). CEP1, the Caenorhabditis elegans p53 homolog, mediates opposing longevity outcomes in mitochondrial electron transport chain mutants. PLoS Genetics. 10(2): e1004097.

Perrin, A.J., Gunda, M., Yu, B., Yen, K., Ito, S., Forster, S., Young, J., Tissenbaum, H.A. & Derry, W.B. (2013). Noncanonical control of C. elegans germline apoptosis by the insulin/IGF-1 and Ras/MAPK signaling pathways. Cell Death and Differentiation. 20(1): 97-107.

Ross, A.J., Li, M., Yu, B., Gao, M.X. & Derry, W.B. (2011). The EEL-1 ubiquitin ligase promotes DNA damage-induced germ cell apoptosis in C. elegans. Cell Death and Differentiation. 18(7): 1140-1149.

Ito, S., Greiss, S., Gartner, A. & Derry, W.B. (2010). Cell-nonautonomous regulation of C. elegans germ cell death by kri-1. Current Biology. 20(4): 333-338.

Gao, X. Liao, E., Yu, B., Wang, Y., Zhen, M. & Derry, W.B. (2008). The SCFFSN-1 ubiquitin ligase controls CEP-1/p53-dependent apoptosis in Caenorhabditis elegans. Cell Death and Differentiation. 15(6): 1054-1062.

Quevedo, C., Kaplan, D.R. & Derry, W.B. (2007). AKT-1 regulates DNA-damage induced germline apoptosis in C. elegans. Current Biology. 17(3): 286-292.

Akira Takeda, University of Turku

Host: Raine Toivonen

Akira Takeda, University of Turku

Host: Raine Toivonen

Simo Nikkari, Center for Military Medicine

Host: Alex-Mikael Barkoff

Simo Nikkari, Center for Military Medicine

Host: Alex-Mikael Barkoff

Paolo Pesaresi and Carlotta Peracchio, Università degli studi di Milano

Paolo Pesaresi and Carlotta Peracchio, Università degli studi di Milano

Dr. Marc Therrien, Université de Montréal, Montreal, Quebec, Canada

Dr. Marc Therrien, Université de Montréal, Montreal, Quebec, Canada

Host: Daniel Abankwa

Turku Cancer Research Society is pleased to announce a daylong seminar on drug discovery and development entitled ‘ACADEMIC CANCER DRUG DEVELOPMENT: Challenges and successes’.

This seminar with distinguished speakers from Finland, Europe and overseas will take place on Monday September 25, 2017 in Congress Centre Mauno, Turku. For more details and registration please visit http://cancerresearch.utu.fi.

Turku Cancer Research Society is pleased to announce a daylong seminar on drug discovery and development entitled ‘ACADEMIC CANCER DRUG DEVELOPMENT: Challenges and successes’.

This seminar with distinguished speakers from Finland, Europe and overseas will take place on Monday September 25, 2017 in Congress Centre Mauno, Turku. For more details and registration please visit http://cancerresearch.utu.fi.

Prof. Frank Claessens, Laboratory of Molecular Endocrinology, Leuven, Belgium

Host: Matti Poutanen

Prof. Frank Claessens, Laboratory of Molecular Endocrinology, Leuven, Belgium

Host: Matti Poutanen

Subhash K. Tripathi, University of Turku

Subhash K. Tripathi, University of Turku

Satu Pekkala, University of Jyväskylä

Host: Eveliina Munukka

Satu Pekkala, University of Jyväskylä

Host: Eveliina Munukka

Dr. Eugene V Koonin, National Center for Biotechnology, Information National Library of Medicine, NIH, Bethesda, USA

Dr. Eugene V Koonin, National Center for Biotechnology Information, National Library of Medicine, NIH, Bethesda, USA

Host: Pere Puigbo (pepuav(at)utu.fi)

Professor James Golden, University California, San Diego:
”Broad-Host-Range Genetic Tools for Cyanobacteria and Heterologous Expression of Natural Products”

Professor Susan Golden, Distinguished Professor Director, University California, San Diego:
”A Day in the Life of a Cyanobacterium: integrating temporal and environmental information”

Professor James Golden, University California, San Diego:
”Broad-Host-Range Genetic Tools for Cyanobacteria and Heterologous Expression of Natural Products”

Professor Susan Golden, Distinguished Professor Director, University California, San Diego:
”A Day in the Life of a Cyanobacterium: integrating temporal and environmental information”

Professor Pirjo Nuutila, University of Turku

Chair: Jorma Toppari

Coffee will be served at 12.00
Seminar 12.15-13.00 is followed by discussion

Professor Pirjo Nuutila, University of Turku

Chair: Jorma Toppari

Coffee will be served at 12.00
Seminar 12.15-13.00 is followed by discussion

The newly formed Turku Metabolomics facility is pleased to announce a seminar to celebrate its opening.

9:30 Welcome and coffee
10:00 Matej Orešič (UTU) – Metabolomics in biomedical research: platforms, challenges, opportunities
10:10 Alex Dickens (UTU) – Biomarkers/Turku core facility
10:30 Jari Sinkkonen (UTU) – Tissue NMR for metabolomics at the NMR Instrument Centre
10:45 Mika Scheinin (UTU/Turku University Hospital) – Pharmacokinetics and verification of drug exposure
11:00 Dawei Geng (Örebro University, Sweden) – Metabolomics at Örebro University and collaboration with Turku Metabolomics facility
11:20 Linda Ahonen (Steno Diabetes Center Copenhagen, Denmark) – Lipidomics with automatized QC – case study: NIST ring trial
11:40 Kati Hanhineva (University of Eastern Finland) – Untargeted metabolomics for nutrition and food research
12:00 Reception and adjourn

The newly formed Turku Metabolomics facility is pleased to announce a seminar to celebrate its opening.

9:30 Welcome and coffee
10:00 Matej Orešič (UTU) – Metabolomics in biomedical research: platforms, challenges, opportunities
10:10 Alex Dickens (UTU) – Biomarkers/Turku core facility
10:30 Jari Sinkkonen (UTU) – Tissue NMR for metabolomics at the NMR Instrument Centre
10:45 Mika Scheinin (UTU/Turku University Hospital) – Pharmacokinetics and verification of drug exposure
11:00 Dawei Geng (Örebro University, Sweden) – Metabolomics at Örebro University and collaboration with Turku Metabolomics facility
11:20 Linda Ahonen (Steno Diabetes Center Copenhagen, Denmark) – Lipidomics with automatized QC – case study: NIST ring trial
11:40 Kati Hanhineva (University of Eastern Finland) – Untargeted metabolomics for nutrition and food research
12:00 Reception and adjourn

Dr. Lorna Young, Laboratory of Prof. Harry Higgs, Geisel School of Medicine, Dartmouth College, USA

Dr. Bert Dhondt, University of Ghent, Belgium

Host: Jyrki Heino (jyrki.heino(at)utu.fi)

Mario Pagano, University of Padova, Italy

Host: Jukka Westermarck

Maijaliisa Erkkola, Dep. of Food and Environmental Sciences, University of Helsinki

Host: Kirsi Laitinen ( kirsi.laitinen@utu.fi )

Michael Brenan, Research Associate, 1CellBio

Host: Hongbo Zhang

Dr. Jan Lammerding, Nancy E. and Peter C. Meinig School of Biomedical Engineering, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, USA

Host: Pekka Taimen

Pirjo Merilahti University of Turku

Host: Sisko Tauriainen

Dr. Vinagolu K. Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center, New York, NY

Host: Johanna Tuomela (jomitu@utu.fi)

Professor David F. Stern, Department of Pathology, Yale University, New Haven, USA

Host: Klaus Elenius

Thorsten Joeris, Lund University, Sweden

Host: Raine Toivonen

Juhani Aakko University of Turku

Host: Arno Hänninen

Prof. Steven Pals, University of Amsterdam, The Netherlands

Host: Sirpa Jalkanen

Professor Benjamin G. Neel, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA

Host: Jukka Westermarck

Teemu Smura University of Helsinki

Host: Sisko Tauriainen

Professor Pirkko Härkönen, University of Turku

Host: Kirsi Laitinen

Professor Brian C. Freeman, Department of Cell & Developmental Biology, University of Illinois, Urbana, Illinois, USA

Host: Lea Sistonen

Professor Hongquan Zhang, Department of Anatomy, Histology and Embryology and Laboratory of Molecular Cell Biology and Tumor

Host: Jyrki Heino

Pirjo Merilahti, University of Turku

Host: Sisko Tauriainen

Professor Dietrich Kabelitz, Department of Immunology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

Host: Jorma Määttä

Professor Henk Stunnenberg, Department of Molecular Biology, Radboud University, Nijmegen, The Netherlands

Host: Riitta Lahesmaa

Academy professor Virpi Lummaa, University of Turku, Turku, Finland

Host: Jyrki Heino

Professor Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

Host: Anna Knittle

Dr. Marco Fritzsche, MRC Human Immunology Unit, Weatherall Institute for Molecular Medicine, University of Oxford, Oxford, UK

Host: Pieta Mattila

Tero Ahola, University of Helsinki

Host: Petri Susi

Professor Jussi Taipale, Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

Host: Jukka Westermarck

Professor Wouter de Laat, Hubrecht Institute, Utrecht, The Netherlands

Host: Riitta Lahesmaa

Speaker: Dr. Julie Bouckaert, University of Lille, France

Speaker: Dr. Julie Bouckaert, University of Lille, France

Prof. Birgit Lane, Institute of Medical Biology and Skin Research Institute of Singapore, Nanyang Technological University, Singapore

Host: Diana Toivola

Dr. Thomas Lilley, Department of Biology, University of Turku & Bucknell University, Lewisburg, USA

Host: Päivi Koskinen

Programme.

Registration (latest on Monday, 5 December)

Programme.

Registration (latest on Monday, 5 December)

Programmme

Registration by 29.11. to contact-tcrs@lists.utu.fi

Please also indicate a possible special diet when registering.

Programmme

Registration by 29.11. to contact-tcrs@lists.utu.fi

Please also indicate a possible special diet when registering.

Siri Tähtinen, University of Helsinki

Host: Laura Kakkola

Prof. Moira O’Bryan, Monash University, Clayton, Victoria, Australia

Host: Anu Sironen

Pieta Mattila, University of Turku

Host: Jukka Alinikula

Prof. Michael McHeyzer-Williams, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, USA

Host: Liu Chengqian

Linnéa Linko, University of Turku

Host: Marianne Gunell

Adj. prof. Adolfo Rivero-Müller, Turku Centre for Biotechnology

Host: Päivi Koskinen

Prof. Ron van Schaik, Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands

Host: Csilla Sipeky

Elina Mäntylä, University of Jyväskylä

Host: Veijo Hukkanen

Olga Vitek, College of Science, College of Computer and Information Science, Northeastern University, Boston, USA

Host: Laura Elo

Olga Vitek, College of Science, College of Computer and Information Science, Northeastern University, Boston, USA

Host: Laura Elo

Pia Rantakari, University of Turku

Host: Eveliina Munukka

Dr. Niina Santio, Department of Biology, University of Turku

Host: Päivi Koskinen

Teemu Kallonen, Sanger Institute, UK

Host: Erkki Eerola

Anthony Chalmers, Institute of Cancer Sciences, University of Glasgow, Scotland, UK

Host: Jukka Westermarck

Prof. Jens Mittag, University of Lübeck, Lübeck, Germany

Host: Jukka Kero

Ulvi Gürsoy, University of Turku

Host: Eija Könönen

Applications of modern mass spectrometry in life sciences

 
Programme and registration (by October 24)

Applications of modern mass spectrometry in life sciences

 
Programme and registration (by October 24)

Adj. prof. Jussi Jäntti, VTT Synthetic Biology Group, Espoo

Host: Päivi Koskinen

Henna-Maria Uusitupa, University of Turku

Host: Eveliina Munukka

Professor Anne Ridley, King´s College London, UK

Host: Päivi Koskinen

Speaker: Adam Byron, Edinburgh Cancer Research UK Centre, University of Edinburgh, UK

Speaker: Adam Byron, Edinburgh Cancer Research UK Centre, University of Edinburgh, UK

Dr. Sophie Rousseaux, INSERM, Université Grenoble Alpes, Institut Albert Bonniot, Grenoble, France

Host: Noora Kotaja